Clinical Study Protocol

Drug Substance	D961H
Study Code	D961HC00006
Date	
Edition	1

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg once daily oral administration with omeprazole 10 mg and D961H 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

Sponsor:

The following Amendment(s) and Administrative Changes have been made to this protocol since the date of preparation:

Amendment No.	**Date of Amendment**

Administrative Change No.	**Date of Administrative Change**

This submission /document contains trade secrets and confidential commercial information, disclosure of which is prohibited without providing advance notice to AstraZeneca and opportunity to object.

PROTOCOL SYNOPSIS

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg once daily oral administration with omeprazole 10 mg and D961H 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

Investigator

The names of the investigators are described in Supplement A, "Investigators and Study Administrative Structure".

Study centre(s) and number of subjects planned

This study will be conducted in approximately 540 randomised subjects recruited from about 70 centres (see Supplement A).

Study period		Phase of development
Estimated date of first subject enrolled	January 2008	Phase III (Therapeutic confirmatory)
Estimated date of last subject completed	September 2009	

Objectives

Primary objective

The primary objective of this study is to evaluate the efficacy of D961H 20 mg once daily (D20) for 24 weeks on maintenance of RE in patients with healed reflux esophagitis (RE) in comparison with omeprazole 10 mg once daily (O10) and D961H 10 mg once daily (D10) by assessment of presence/absence of recurrence of RE throughout the treatment period (from the randomisation to the treatment completion) according to the Los Angeles (LA) classification (Lundell LR, et al., 1999).

Secondary objectives

The secondary objectives are as follows:

- To evaluate the efficacy of D20 on maintenance of healed RE in comparison with O10 and D10 by assessment of the presence/absence of recurrence of RE at Week 4 or before and Week 12 or before according to the LA classification.

- To evaluate the efficacy of D20 on gastroesophageal reflux disease (GERD) symptoms in comparison with O10 and D10 by assessment of the presence/absence and the severity of investigator-reported symptoms at Week 4, 8, 12, 16, 20 and 24.

- To evaluate the safety and tolerability of D10, D20 and O10 in long-term administration (at Week 24) by assessment of adverse events (AEs), laboratory test values and vital signs (blood pressure and pulse rate).

Study design

This is a multicentre, randomised, double-blind, double dummy, parallel-3 group study on the patients with healed RE.

Target subject population

Male and female patients aged 20 years or over, with endoscopically verified healed RE after initial treatment in the preceding study (D961HC00002), or general treatment with a proton pump inhibitor (PPI).

Investigational product, dosage and mode of administration

In this study, the following products will be used.

- D961H capsule 20 mg

  One capsule of D961H capsule 20 mg and 1 tablet of omeprazole tablet placebo will be orally administered once daily after breakfast for a maximum of 24 weeks in patients randomised into the D20 group.

- D961H capsule 10 mg
  One capsule of D961H capsule 10 mg and 1 tablet of omeprazole tablet placebo will be orally administered once daily after breakfast for a maximum of 24 weeks in patients randomised into the D10 group.

Comparator, dosage and mode of administration

- Omeprazole tablet 10 mg
  One tablet of omeprazole tablet 10 mg and 1 capsule of D961H capsule placebo will be orally administered once daily after breakfast for a maximum of 24 weeks in patients randomised into the O10 group.

Duration of treatment

A maximum of 24 weeks

Outcome variables

– **Efficacy**

– **Primary outcome variable:**

- Presence/absence of recurrence of RE throughout the treatment period according to LA classification.

– **Secondary outcome variables:**

[Maintenance of healed RE]

- Presence/absence of recurrence of RE at Week 4 or before and Week 12 or before according to LA classification.

[GERD symptoms]

- Presence/absence of each GERD symptom based on the severity assessment for 7 days before the scheduled visits at Week 4, 8, 12, 16, 20 and 24.

– **Safety**

- AEs
- Laboratory test values
- Vital signs (blood pressure, pulse rate)

Statistical methods

The endoscopically verified recurrence of RE is handled as an event. The time to event from the starting day of study drug administration will be analysed by Kaplan-Meier method and Kaplan-Meier plot will be prepared for each group. The time curve of D20 will be compared to those of D10 and O10 by Log-rank test. The no-relapse rates at Week 4, 12 and 24 and their two-sided 95% confidence intervals will be calculated for each group.

For safety variables, quantitative data will be summarised for each treatment group using descriptive statistics and qualitative data will be summarised for each treatment group using a frequency table.

TABLE OF CONTENTS PAGE

TITLE PAGE 1
PROTOCOL SYNOPSIS 2
TABLE OF CONTENTS 5
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS 9
1. INTRODUCTION 11
1.1 Background 11
1.2 Rationale 13
2. STUDY OBJECTIVES 14
2.1 Primary objective 14
2.2 Secondary objectives 14
3. STUDY PLAN AND PROCEDURES 14
3.1 Overall study design and flow chart 14
3.2 Rationale and risk/benefit assessment 18
3.2.1 Rationale for study design, doses and control groups 18
3.2.2 Risk/benefit and ethical assessment 19
3.3 Selection of study population 20
3.3.1 Study selection record 20
3.3.2 Inclusion criteria 20
3.3.3 Exclusion criteria 21
3.3.4 Restrictions 24
3.3.5 Discontinuation of subjects from treatment or assessment 24
3.3.5.1 Criteria for discontinuation 24
3.3.5.2 Procedures for discontinuation 24
3.4 Treatments 25
3.4.1 Identity of investigational products 25
3.4.2 Doses and treatment regimens 26
3.4.3 Labeling 26
3.4.4 Storage 26
3.4.5 Accountability 26
3.5 Method of assigning subjects to treatment groups 27
3.6 Blinding and procedures for unblinding the study 29
3.6.1 Methods for ensuring blinding 29
3.6.2 Methods for unblinding the study 29

3.7 Pre-study, concomitant and post-study treatment(s) 30
3.7.1 Allowable concomitant treatments 30
3.7.2 Prohibited concomitant treatments 30

3.8 Treatment compliance 31

4. MEASUREMENTS OF STUDY VARIABLES AND DEFINITIONS OF OUTCOME VARIABLES 31

4.1 Primary variable 31

4.2 Screening and demographic measurements 31
4.2.1 Hp test (IgG antibody) 33

4.3 Patient-Reported Outcomes (PRO) (Not applicable) 33

4.4 Health Economic measurements and variables (Not applicable) 33

4.5 Pharmacokinetic measurements and variables (Not applicable) 33

4.6 Efficacy and pharmacodynamic measurement and variables 33
4.6.1 Preventive effect of recurrence of RE according to LA classification 34
4.6.1.1 EGD 34
4.6.1.2 Method of assessment 35
4.6.2 Investigator-reported symptoms 35

4.7 Safety measurements and variables 36
4.7.1 AEs 37
4.7.1.1 Definitions 37
4.7.1.2 Recording of AEs 38
4.7.1.3 Reporting of SAEs 40
4.7.2 Laboratory safety measurements and variables 41
4.7.2.1 Test items 41
4.7.2.2 Methods of assessment 42
4.7.3 Vital signs and physical examination 43

4.8 Volume of blood sampling and handling of biological samples 43
4.8.1 Analysis of biological samples 44
4.8.1.1 Biochemistry samples 44

4.9 Genetic test 44
4.9.1 Purpose of genetic test 44
4.9.2 Collection of samples for genetic research 44
4.9.3 Storage and coding of samples for genetic test 44

5. DATA MANAGEMENT 45

6. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE 46

6.1 Statistical evaluation – general aspects 46

6.2 Description of outcome variables in relation to objectives and hypotheses 46
6.2.1 Primary outcome variables 46

6.2.2 Secondary outcome variables....46
6.3 Description of analysis sets....46
6.4 Method of statistical analysis....47
6.4.1 Primary outcome variables....47
6.4.2 Secondary outcome variables....48
6.4.2.1 Efficacy....48
6.4.2.2 Safety variables....48
6.5 Determination of sample size....49
6.6 Interim analyses (Not applicable)....49
6.7 Central evaluation committee....49
7. STUDY MANAGEMENT....49
7.1 Monitoring....49
7.1.1 Direct access to source data in Japan....50
7.2 Audits and inspections....50
7.3 Training of staff....51
7.4 Changes to the protocol....51
7.5 Study agreements....51
7.6 Study timetable and end of study....52
7.6.1 Planned duration of the study....52
7.6.2 Discontinuation or suspension of the whole study programme....52
7.6.3 Completion of the study....52
7.6.4 Deviations from the protocol and the recording....52
7.6.5 Archiving of records at the study centre....53
7.6.5.1 Filing of study related materials....53
7.6.5.2 Archiving period....53
8. ETHICS....54
8.1 Ethics review....54
8.2 Ethical conduct of the study....54
8.3 Informed consent....54
8.4 Subject data protection....55
9. PROCEDURES IN CASE OF EMERGENCY, OVERDOSE OR PREGNANCY....55
9.1 AstraZeneca emergency contact procedure....55
9.2 Procedures in case of medical emergency....56
9.3 Procedures in case of overdose....56
9.4 Procedures in case of pregnancy....57

10. REFERENCES 57

LIST OF TABLES PAGE

Table 1 Study plan 16
Table 2 Investigational products.....25
Table 3 Combination of investigational products.....26
Table 4 Efficacy objective and outcome variable.....33
Table 5 Safety objective and outcome variable.....37
Table 6 The items of laboratory safety.....42
Table 7 Volume of blood to be drawn from each subject.....43

LIST OF FIGURES PAGE

Figure 1 Study flow chart 15
Figure 2 Flow chart for subject registration and prescription of the investigational product 28

LIST OF APPENDICES

Appendix A Signatures
Appendix B Additional Safety Information
Appendix C Handling of genetic samples
Appendix D Medical Interview Form

LIST OF SUPPLEMENTS

Supplement A Investigators and Study Administrative Structure

LIST OF ABBREVIATIONS AND DEFINITION OF TERMS

The following abbreviations and special terms are used in this study protocol.

Abbreviation or special term	Explanation
AE	Adverse event (see definition in Section 4.7.1.1)
ALP	Alkaline phosphatase
ALT (GPT)	Alanine aminotransferase (Glutamic pyruvic transaminase)
AST (GOT)	Aspartate aminotransferase (Glutamic oxaloacetic transaminase)
BUN	Blood urea nitrogen
CK (CPK)	Creatine kinase (Creatine phosphokinase)
COX-2	Cyclooxygenase-2
CYP	Cytochrome P450
D10	D961H 10 mg once daily
D20	D961H 20 mg once daily
eCRF	electronic Case Report Form
EGD	Esophagogastroduodenoscopy
EM	Extensive Metaboliser
FAS	Full Analysis Set
GCP	Good Clinical Practice
GERD	Gastroesophageal reflux disease
γ-GTP	γ-Glutamyltranspeptidase
HIV	Human Immunodeficiency Virus
Hp	*Helicobacter pylori*
HRQOL	Health related quality of life
ICH	International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use
IgG	Immunoglobulin G
Investigator(s)	Principal investigators and sub-investigators in this protocol
LA	Los Angeles
LDH	Lactate dehydrogenase
MedDRA	Medical Dictionary for Regulatory Activities
NSAID	Non-steroidal anti-inflammatory drug
O10	Omeprazole 10 mg once daily

Abbreviation or special term	Explanation
OAE	Other Significant Adverse Event (ie, adverse events of particular clinical importance, other than SAEs and those AEs leading to discontinuation of the subject from study treatment; see definition in Section 4.7.1.1).
PM	Poor Metaboliser
PPS	Per Protocol set
PRO	Patient reported outcomes
Principal investigator	A person responsible for the conduct of a clinical study at a study site. Every study site has a principal investigator.
RE	Reflux esophagitis
SAE	Serious adverse event (see definition in Section 4.7.1.1).
SAP	Statistical Analysis Plan
WBDC	Web Based Data Capture

1. INTRODUCTION

1.1 Background

Reflux esophagitis (RE) is a disease that causes mucosal damage in the esophagus due to reflux of gastric acid. The incidence of RE is sharply increasing in Japan along with the aging of society, Westernization of dietary life and increase in the prevalence of obesity. Marked adverse influence on the health-related quality of life (HRQOL) is observed in the patients with RE due to the symptoms of epigastric pain and acid regurgitation including the heartburn that is the primary symptom of gastric acid reflux.

For the treatment of this disease in Japan, H_2 receptor antagonist was approved in 1982. Subsequently in 1991, proton pump inhibitor (PPI) whose action to inhibit gastric acid secretion is superior to H_2 receptor antagonist was approved. Omeprazole is a PPI that is extensively used in clinical practice in Japan and abroad. Its efficacy and safety have been evidenced in the initial treatment of RE as well as in the maintenance treatment against the recurrence and relapse after the initial treatment.

D961H (generic name: esomeprazole) is a PPI and is the S-enantiomer of racemate omeprazole. Its features are as follows:

- The metabolic rate by cytochrome P450 (CYP) isoform, CYP2C19, is lower than that of omeprazole the impact of genetic effect is less pronounced than for omeprazole.
- The first pass effect in the liver is less than omeprazole.
- The inter-individual variation in antisecretory effect is less than omeprazole.

D961H has a low systemic toxicity after repeated oral administration to rats and dogs. All findings noted have also been seen after treatment with omeprazole. Results of the reproductive and genetic toxicity tests for D961H did not indicate a risk to humans. Exposure to D961H in animals in the toxicology studies was sufficient to support an adequate margin of safety for clinical use.

In overseas clinical studies to assess pharmacokinetics, D961H was rapidly absorbed with maximal plasma concentration (C_{max}) reached within 1 to 2 hours after oral administration to humans. A bioavailability was 64% after a single dose of 40 mg and 89% after repeated dosing of 40 mg. The elimination half-life ($t_{½}$) in CYP2C19 extensive metaboliser (EM) was 0.9 hours after a single dose and 1.3 hours after repeated dosing. The metabolic rate of D961H was decreased in patients with severe liver dysfunction, but not decreased in those with mild or moderate liver dysfunction.

Results from overseas clinical studies to examine the drug interaction suggested that D961H inhibit CYP2C19, but not CYP3A4.

In overseas clinical studies to assess the efficacy and safety of D961H, results from Phase I studies (approximately 860 subjects), indicated a more pronounce and sustained acid inhibition than the corresponding dosed of omeprazole. Four initial treatment (up to 8 weeks) studies (SH-QBE-0013/172, SH-QBE-0016/173, SH-QBE-0017/174, SH-QBE-0052/222) were conducted in patients with RE and two maintenance treatment studies (SH-QBE-0014/177, SH-QBE-0015/178) were conducted in patients who had complete healing of their RE in one of the initial treatment studies. In the initial treatment studies, 6709 patients were randomised, and D961H 20 mg once daily and/or 40 mg once daily were compared with omeprazole 20 mg once daily. D961H 40 mg given once daily resulted in higher healing rates than did omeprazole 20 mg once daily for the healing of RE after both 4 and 8 weeks of treatment and the Life Table estimated difference after 8 weeks was significant in study SH-QBE-0013/172 ($p<0.001$) and in study SH QBE 0052/222 ($p=0.0001$). D961H 20 mg and 40 mg once daily provided high healing rates of RE at Week 8 (D961H 20 mg: 89.9-90.6%; D961H 40 mg: 92.2-94.1%). In the maintenance treatment studies, 693 patients were randomised, and 3 doses of D961H - 10 mg, 20 mg, and 40 mg - were compared with placebo. All doses of D961H effectively maintained healing across all grades of Los Angeles (LA) classification (Lundell LR, et al., 1999) of RE and controlled heartburn and other symptoms of GERD (Maintenance of RE Life Table estimated healing rates at Month 6, SH-QBE-0014/177: D961H 10 mg 54.2% [$p<0.001$], 20 mg 78.7% [$p<0.001$], 40 mg 87.9% [$p<0.001$], placebo 29.1%; SH-QBE-0015/178: D961H 10 mg 57.1% [$p<0.001$], 20 mg 93.2% [$p<0.001$], 40 mg 93.6% [$p<0.001$], placebo 29.0%). On the other hand, the frequency of adverse events (AEs) in comparative studies with omeprazole of initial treatment on the healing effect of RE (SH-QBE-0013/172, SH-QBE-0016/173, SH-QBE-0017/174, SH-QBE-0052/222) and placebo controlled studies of maintenance treatment on the maintenance effect of healed RE (SH-QBE-0014/177, SH-QBE-0015/178) were almost the same between D961H and omeprazole group, and D961H and placebo group. In addition, the profile of reported AEs for the maintenance treatment up to 1 year was similar to that seen in the initial treatment. The laboratory variables, such as haemoglobin, serum iron, serum vitamin B_{12}, did not indicate any significant changes over time. Also, the subsequent post-marketing surveillance data in overseas have been the same as safety data resulted from these clinical studies.

In Japan, Phase I single dose study (SH-QBE-0094) and repeated dosing study (SH-QBE-0098) with healthy adult males were conducted. The safety and pharmacokinetics for D961H 10 mg, 20 mg and 40 mg were assessed in the single dose study, and 24-hour intragastric pH monitoring after 5-day administration was conducted in the repeated dosing study to assess the antisecretory effect of D961H. Both the single dose and the repeated dosing were well tolerated. Prospectively compared with data from the study with Caucasian (SH-QBE-0095), the level of pharmacokinetic profiles and antisecretory effect were similar to that in Japanese who has the same genotype as Caucasian. The safety profiles of D961H 10 mg, 20 mg and 40 mg in Caucasian were similar to the one in Japanese.

Based on the above results, the significant efficacy and safety of D961H are also expected in Japan for acid-related gastrointestinal diseases as well as omeprazole.

Approval status of D961H in overseas

D961H for oral use has been approved in more than 95 countries as of August 2006, and its indications are:

- healing of erosive RE and long-term management of patients with healed esophagitis to prevent relapse
- symptomatic treatment of gastroesophageal reflux disease (GERD) (adults and 12-18 year old children)
- in combination with an appropriate antibacterial therapeutic regimen for the eradication of *Helicobacter pylori* (Hp) and treatment of concurrent duodenal ulcers
- treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug (NSAID) therapy
- healing of gastric ulcers associated with NSAID therapy, including selective cyclooxygenase 2 (COX-2) inhibitors
- prevention of gastric and duodenal ulcers associated with NSAID therapy, including selective COX-2 inhibitors, in patients at risk
- treatment of pathological gastric acid hypersecretory conditions including Zollinger-Ellison Syndrome

1.2 Rationale

D961H is the S-enantiomer of racemate omeprazole. Omeprazole has a pronounce and sustained antisecretory effect and has been confirmed as the useful drug for acid-related diseases such as RE. The results of clinical studies conducted abroad indicated that D961H has the same or more clinical effect on RE in comparison with omeprazole, and D961H has been approved abroad for the indication of healing and maintenance treatment of RE same as omeprazole. The results of Phase I clinical studies (SH-QBE-0094, SH-QBE-0098) conducted in Japan showed that D961H was well tolerated. Prospectively compared with data from the study with Caucasian (SHQBE-0095), the level of pharmacokinetic profiles and antisecretory effect were similar to that in Japanese who has the same genotype as Caucasian. The safety profiles in Caucasian were also similar to the one in Japanese. Based on the above results, the significant efficacy and safety of D961H are also expected in Japan for RE. Accordingly, it was considered valid to conduct this clinical study to verify the recurrence prevention effect as well as safety of D961H in RE using omeprazole as the comparator because omeprazole is extensively used in the initial treatment and maintenance therapy of this target disease and its efficacy and safety have been verified. As in the case of omeprazole, D961H is metabolised by CYP2C19 but D961H is characterised in that the proportion metabolised by CYP2C19 is lower and the influence of genotype is less in comparison with omeprazole. In this regard, it was decided to conduct a genetic test in this

clinical study to also investigate the influence of CYP2C19 genotype on the recurrence prevention effect of D961H and omeprazole in RE.

2. STUDY OBJECTIVES

2.1 Primary objective

The primary objective of this study is to evaluate the efficacy of D961H 20 mg once daily (D20) for 24 weeks on maintenance of RE in patients with healed reflux esophagitis (RE) in comparison with omeprazole 10 mg once daily (O10) and D961H 10 mg once daily (D10) by assessment of presence/absence of recurrence of RE throughout the treatment period (from the randomisation to the treatment completion) according to the LA classification.

2.2 Secondary objectives

The secondary objectives of the study are as follows:

- To evaluate the efficacy of D20 on maintenance of healed RE in comparison with O10 and D10 by assessment of the presence/absence of recurrence of RE at Week 4 or before and Week 12 or before according to the LA classification.
- To evaluate the efficacy of D20 on GERD symptoms in comparison with O10 and D10 by assessment of the presence/absence and the severity of gastrointestinal investigator-reported symptoms at Week 4, 8, 12, 16, 20 and 24.
- To assess the safety and tolerability of D10, D20 and O10 in long-term administration (at Week 24) by assessment of adverse events (AEs), laboratory test values and vital signs (blood pressure and pulse rate).

3. STUDY PLAN AND PROCEDURES

3.1 Overall study design and flow chart

This Clinical Study Protocol has been subjected to a peer review according to AstraZeneca standard procedures.

This is a multicentre, randomised, double-blind, double dummy, parallel-three group study to evaluate the efficacy and safety of D10, D20 and O10 in healed RE patients in long-term administration (at Week 24).

After initial treatment in the preceding study (D961HC00002), or general treatment with a PPI, the subjects with endoscopically verified healed RE and judged as eligible by the test at the time of screening are randomised to D10 group, D20 group or O10 group at the ratio of 1:1:1. In the case of subjects who have participated in the preceding study (D961HC00002), the data obtained at the end of the preceding study (D961HC00002) (the data obtained at the

latest visit after Visit 3 [Visit 2, if RE healed at Week 4] of the preceding study [D961HC00002] for the laboratory test values) are used as the screening data in this study.

Endoscopic examination is done at Week 4, 12 and 24 to check whether the RE recurred or not. If the recurrence is observed at Week 4 or before and at Week 12 or before in a subject, then the subject will discontinue the study at the time point. The investigational product administration period is maximum 24 weeks. In addition to checking the safety throughout the study period (from the day of informed consent to the day of the last scheduled visit or withdrawal), the GERD symptoms are assessed by the investigator(s) on the basis of medical interview form filled in by the subject.

A patient whose RE is healed in the preceding study (D961HC00002) may be enrolled in this study after the informed consent and the eligibility assessment. The investigator(s) will obtain the signed written informed consent for this study from a patient within 3 weeks prior to Visit 2 of this study.

All EGD images of all patients allocated the study drugs during the study period will be reviewed by the central evaluation committee (see Section 6.7) established by AstraZeneca K.K. under the blinded conditions as needed.

Figure 1 and Table 1 present the study flow chart and the schedule of the study.

Figure 1 Study flow chart



* If recurrence of RE is confirmed in a subject by EGD, the subject will be discontinued from the study at the time.

Table 1 Study plan

	Screening		**Study Treatment**					
		Randomisation						
Visit	**1[1)]**	**2**	**3** **Week 4**	**4** **Week 8**	**5** **Week 12**	**6** **Week 16**	**7** **Week 20**	**8 (or at discontinuation)** **Week 24**
Days after Visit 2	**-7 to 0**	**0**	**28**	**56**	**84**	**112**	**140**	**168**
Time window (days)	**-**	**-**	**±4**	**±4**	**±4**	**±4**	**±4**	**±4**
Informed consent [2)]	X							
Inclusion/exclusion criteria	X	X[11)]						
Demographic data	X							
Medical/surgical history	X							
Underlying diseases	X	X						
Physical examination	X	X	X	X	X	X	X	X
Vital signs	X		X	X	X	X	X	X
Clinical laboratory tests [3)]	X		X		X			X
Pregnancy test (urine) [4)]	X							
Hp test (IgG antibody)	X[8)]							
Genetic test for CYP2C19	X[8)]							
GERD symptoms assessed by the investigator [5)]		X	X	X	X	X	X	X
EGD [6)]		X[9), 10)]	X[12)]		X[12)]			X
Randomisation		X						
Dispense investigational products		X	X	X	X	X	X	

Table 1 Study plan

	Screening		Study Treatment					
		Randomisation						
Visit	**1[1)]**	**2**	**3** **Week 4**	**4** **Week 8**	**5** **Week 12**	**6** **Week 16**	**7** **Week 20**	**8 (or at discontinuation)** **Week 24**
Days after Visit 2	**-7 to 0**	**0**	**28**	**56**	**84**	**112**	**140**	**168**
Time window (days)	**-**	**-**	**±4**	**±4**	**±4**	**±4**	**±4**	**±4**
Review/Collect returned investigational products			X	X	X	X	X	X
Check concomitant medications	←	—	—	—	—	—	—	→
AEs [7)]	←	—	—	—	—	—	—	→

1) In the case of subjects whose RE is healed by the initial treatment in the preceding study (D961HC00002) and enrolled in this study, the data at the end of preceding study (D961HC00002) (the data obtained at the latest visit after Visit 3 [Visit 2, if RE healed at Week 4] of the preceding study [D961HC00002] for the laboratory test values) are used as the Visit 1 data (excluding the pregnancy test. Refer to footnotes 3, 4 and 10 also.).
2) The signed informed consent for this study should be within 3 weeks (21 days) prior to Visit 2 (randomisation) of this study regardless of the background of healed RE (by initial treatment in the preceding study [D961HC00002] or by general treatment).
3) A central laboratory is used for laboratory tests in all the subjects. In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, if the results of test conducted within 2 weeks prior to randomisation at the laboratory test department of each participating medical institution are available at Visit 1, the eligibility may be checked using these test values even if obtained before informed consent. However, the baseline laboratory test values should be determined within 1 week before randomisation at the central laboratory.
4) Conducted in pre-menopausal females with a child-bearing potential. For the purpose of checking the eligibility (see Section 3.3.3), the pregnancy test is essential regardless of the background of healed RE (by the initial treatment in the preceding study [D961HC00002] or by general treatment).
5) The subject fills in the overall severity of GERD symptoms in the medical interview form (Appendix D). The investigator(s) checks the medical interview form and evaluates each symptom according to the severity classification.
6) Conducted in fasting condition.
7) As to serious adverse events (SAEs) and AEs resulting in discontinuation, all those that occur after informed consent are recorded in the electronic case report form (eCRF). As to the AEs other than serious or resulting in discontinuation, those that occur from the start of investigational product administration to the day of the last scheduled visit or withdrawal are stated in eCRF.

8) In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, the test may be conducted at any visit during the treatment period until the discontinuation or completion of this study if it is not possible to conduct it at the time of screening.
9) In the case of subjects whose RE is healed by general treatment and after that give informed consent and are enrolled in this study on the same day, the results of test conducted on randomisation day are available, these data may be used with the consent of subject even if obtained before informed consent.
10) In the case of subjects whose RE is healed by the initial treatment in the preceding study (D961HC00002) and enrolled in this study, the EGD data at the end of preceding study (D961HC00002) are used as the baseline data in this study.
11) In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, the duration of the treatment period with PPI by general treatment should be within 12 weeks at Visit 2 (randomisation day) (see Section 3.3.2).12) When recurrence of RE is observed by EGD, this study is discontinued.

3.2 Rationale and risk/benefit assessment

3.2.1 Rationale for study design, doses and control groups

Rationale for doses

In a long-term study conducted in Japanese patients with H_2 receptor antagonist resistant RE to investigate omeprazole 10 mg, 20 mg and famotidine 40 mg, the result showed that non-relapse rates up to Week 24 by EGD were 59.8% and 87.3% in omeprazole 10 mg and 20 mg, respectively.

In an overseas study (SH-QBE-0014/177), non-relapse rates of RE up to Week 24 were 54.2%, 78.7% and 87.9% in D961H 10 mg, 20 mg and 40 mg, respectively. Thus, non-relapse rates in all D961H groups were significantly higher than that in placebo group (29.1%). Meanwhile, in another overseas study (SH-QBE-0015/178), non-relapse rates of RE up to Week 24 were 57.1%, 93.2% and 93.6% in D961H 10 mg, 20 mg and 40 mg, respectively. Thus, non-relapse rates in all the D961H groups were significantly higher than that in the placebo group (29.0%). In maintenance treatment, the effect of D961H 40 mg was not so enhanced as in initial treatment of RE, and it is considered that its preventive effect for recurrence of RE reaches a plateau at 20 mg. Judging from the above results, D961H 20 mg is recommended to be given for maintenance therapy of RE abroad.

As described in the above, the optimal dose of D961H is considered as 20 mg in the maintenance treatment of RE in Japan because the recurrence rates of RE in omeprazole 10 mg in Japan and D961H 10 mg in overseas are higher than that in omeprazole 20 mg in Japan and D961H 20 mg in overseas. However, considering that the approved dose of omeprazole in the maintenance treatment of RE in Japan is 10-20 mg. Therefore, it was decided to compare D961H 20 mg with omeprazole 10 mg and D961H 10 mg in this study.

Rationale for setting the length of treatment period

Based on the duration of treatment in previous clinical studies of maintenance treatment for RE, the treatment period was set to be a maximum of 24 weeks for this study.

Rationale for selecting comparator groups

The approved dose of omeprazole in the maintenance treatment of RE in Japan is 10-20 mg. Omeprazole 10 mg once daily is provided as the comparator group to evaluate the clinical positions of omeprazole 10 mg, D961H 10 mg and 20 mg in this study.

Rationale for a genetic test

As D961H is mainly metabolised by CYP2C19 whose polymorphism is known, the genotype of CYP2C19 is considered to influence the efficacy and safety of D961H. It was decided to conduct a genetic test in order to evaluate the influence of CYP2C19 genotype on the recurrence prevention effect of D961H.

Rationale for an Hp test

According to the Hp infection diagnosis and treatment guideline (revised in 2003) by the Japanese Society for Helicobacter Research, GERD including RE is cited as one of the "diseases investigated for the significance of Hp eradication". There is a report (Kuipers EJ, et al., 1996) that the eradication is necessary because PPI aggravated the atrophy of stomach mucosa in Hp-positive GERD patients under long-term treatment with PPI. However, since this report is not supported by Food and Drug Administration, no conclusion has been reached up to present. On the other hand, it was anticipated that Hp eradication could lead to GERD aggravation and Barrett's esophagus increase, increasing the incidence of lower esophageal adenoma (Labenz J, et al., 1997). However, such possibility is considered negligible at present (Befrits R, et al., 2000, Moayyedi P, et al., 2001, Sugiyama T, 2003). Accordingly, further investigation on the relation of Hp infection and eradication to RE is considered necessary. Therefore, it was decided to collect information on the presence or absence of Hp infection in this study.

Rationale for assessment of GERD symptoms

RE is a disease that causes mucosal damage in the esophagus due to reflux of gastric acid and associated with the symptoms of acid regurgitation, epigastric pain and dysphagia including the heartburn that is the primary symptom of gastric acid reflux. Therefore, it was decided to obtain relevant data on every scheduled visit using the medical interview form (Appendix D) to evaluate the GERD symptoms in detail for objective severity assessment by investigator(s).

3.2.2 Risk/benefit and ethical assessment

D961H is a PPI and is the S-enantiomer of racemate omeprazole.

Omeprazole was approved in Japan on 18 January 1991 for the indication for gastric ulcer, duodenal ulcer, anastomotic ulcer, RE, and Zollinger-Ellison syndrome at a dose of 10 to 20 mg given once daily. Omeprazole has been widely used in the clinical practice and the efficacy and safety of the drug have been well established.

Meanwhile, D961H has not been approved in Japan but it has been approved in more than 95 overseas countries, mainly for the treatment of GERD. The evaluation of the postmarketing

surveillance data, after more than 397 million delivered treatment courses (as of 10 August 2006), has not revealed any unexpected safety issues.

In Japan, the tolerability of repeated administration of placebo (18 subjects), D961H 10 mg (24), 20 mg (24) and 40 mg (24) once daily for 5 days was examined in 90 healthy Japanese subjects (SH-QBE-0098). Two AEs (pharyngeal discomfort and epigastric discomfort) were observed in 40 mg group, and one AE (a common cold) was observed in 20 mg group. As all 3 AEs were of mild intensity and assessed as not related to D961H, it was judged that there is no safety concern about conducting the study.

3.3 Selection of study population

3.3.1 Study selection record

Investigator(s) must keep a record of subjects who were considered for enrolment but were never enrolled eg, subject screening log. This information is necessary to establish that the subject population was selected without bias.

3.3.2 Inclusion criteria

For inclusion in the treatment period (subject registration) subjects must fulfil all of the following criteria:

1. Provision of written informed consent (including written informed consent to a genetic test)

2. Patients have to fulfil either of the following criteria:

   - Patients with healed RE verified by EGD in the preceding study (D961HC00002)

   - Patients with endoscopically verified healed RE by EGD receiving general treatment with PPI

     - Endoscopically verified RE classified into LA Classification Grade A, B, C or D within 2 weeks prior to initiation of the general treatment with PPI

     - Duration of the treatment period with PPI is 12-week or shorter. The last PPI administration by general treatment must be within 1 week before randomisation

3. Patients who are able to answer medical interview form.

Rationale for inclusion criteria

1. Established as the part of ethics requirements in accordance with ‘Good Clinical Practice (GCP).

2. In general, RE is diagnosed by EGD. Since LA classification is the commonly used diagnostic criterion of EGD in the world, and LA classification Grade A to D is classified as RE, the criterion was decided to be used in this study.

3. Established because the answer to Medical Interview Form by the patients is necessary for the evaluation of the secondary objectives.

3.3.3 Exclusion criteria

Any of the following is regarded as a criterion for exclusion from the study:

1. Male or female aged less than 20 years at the time of informed consent.

2. Patients with current or historical evidence of the following gastrointestinal diseases/conditions:

   – Esophageal stricture

   – Primary esophageal motility disorder(s) (diffuse esophageal spasm, achalasia)

   – Systemic sclerosis (scleroderma)

   – Irritable Bowel Syndrome

   – Inflammatory bowel disease

   – Zollinger-Ellison syndrome

   – Malabsorption syndrome

3. Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation

4. Previous esophageal, gastric or duodenal surgery except simple closure of perforated ulcer

5. Patients with current or a history of significant or unstable:

   – Cardiovascular diseases or cardiac chest pain

   – Cerebrovascular diseases, such as cerebral ischemia, infarction, or haemorrhage

   – Diabetes mellitus uncontrolled on dietary management, exercise therapy or medication

- Pulmonary, renal, pancreatic or liver diseases or any other serious diseases as judged by the investigator(s) to interfere with the evaluation of the current study

- For the patients whose RE has prospects (or was confirmed) to be healed in the preceding study (D961HC00002) and will be enrolled in this study, hepatic enzymes (AST [GOT], ALT [GPT] or ALP) or total bilirubin is more than or equal to three times of the upper limit of normal at the latest visit after Visit 3*, and for the patients whose RE were healed by general treatment and will be enrolled in this study, hepatic enzymes (AST [GOT], ALT [GPT] or ALP) or total bilirubin is more than or equal to three times of the upper limit of normal within 2 weeks prior to randomisation.
  * Visit 2, if RE is healed at Week 4

- For the patients whose RE has prospects (or was confirmed) to be healed in the preceding study (D961HC00002) and will be enrolled in this study, serum creatinine is greater than 2.0 mg/dL at the latest visit after Visit 3*, and for the patients whose RE were healed by general treatment and will be enrolled in this study, serum creatinine is greater than 2.0 mg/dL within 2 weeks prior to randomisation.
  * Visit 2, if RE is healed at Week 4

- Malignant disease (except for minor superficial skin disease)

- Generalised bleeding disorders

- Any conditions that will require surgery during the study period (from the day of informed consent to the last scheduled visit or withdrawal)

6. Need for continuous concomitant therapy with:

- PPI (except for the investigational product)

- H_2 receptor antagonist

- M_1 receptor antagonist

- Hp eradication therapy

- Antacids

- Anticholinergics used for GI indications

- Gastrointestinal promotility drugs (eg, metoclopramide)

- Prostaglandin analogs having the indication of peptic ulcer (eg, misoprostol)

- Antineoplastic drugs
- Gastroprotective agents
- Bisphosphonates (eg, etidronate disodium, alendronate sodium)
- Steroids (oral, intravenous, suppository)
- Drugs that are known to induce drug interaction with D961H and/or omeprazole (eg, human immunodeficiency virus [HIV] proteinase inhibitors including atasanavir sulphate, diazepam, phenitoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole)

7. Endoscopic Barrett's esophagus (3 cm or longer Barrett's epithelium) or significant dysplastic changes in the esophagus

8. Pregnancy or lactation. Women of childbearing potential must have a negative urine pregnancy test at screening, and maintain effective contraception during the study period as judged by the investigator.

9. Use of any other investigational compounds or participation in another clinical study (except for the preceding Study [D961HC0002]) within 4 weeks before randomisation.

10. Prior randomisation in this study

11. Any significant "alarm symptoms" within the past 24 weeks before randomisation, such as, unintentional weight loss, gastrointestinal bleeding, jaundice, or any other signs indicating serious or malignant disease.

12. Patients with diseases/symptoms such as allergy or sensitivity to PPIs in whom the investigational products are contraindicated

13. Any history of a generalised bleeding disorder resulting from haemorrhagic diathesis (eg, abnormalities in clotting factors or platelets)

14. History of drug addiction or alcoholism within the past 12 months before randomisation

15. Inability to understand or provide informed consent

16. Inability or unwillingness to take the investigational products as instructed

17. Inability to undergo EGD or unwillingness to undergo multiple EGDs.

18. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)

Rationale for exclusion criteria

Since the above underlying diseases, concurrent medications, and conditions may affect evaluation of effects of the investigational products in preventing recurrence of RE and these exclusion criteria are considered to be necessary for the safety of subjects, these exclusion criteria were established.

3.3.4 Restrictions

Subjects must follow the following restrictions during the study period:

- The subject must fast according to the procedures specified by the study centre before EGD.

3.3.5 Discontinuation of subjects from treatment or assessment

3.3.5.1 Criteria for discontinuation

Subjects may be discontinued from study treatment and assessments at any time. Specific reasons for discontinuing a subject from this study are:

- Voluntary discontinuation by the subject who is at any time free to discontinue his/her participation in the study, without prejudice to further treatment
- Safety reasons as judged as the patient to be discontinued by the investigator(s) and/or AstraZeneca KK
- Severe non-compliance to protocol as judged by the investigator(s) and/or AstraZeneca KK
- Incorrect enrolment, ie, the subject does not meet the required inclusion/exclusion criteria for the study
- Subject lost to follow-up
- Occurrence of an event in conflict of exclusion criteria (eg, development of gastric or duodenal ulcer, pregnancy)
- The recurrence of RE confirmed by EGD
- Others as judged appropriate by the investigator(s) (reasons for discontinuation must be recorded in eCRF)

3.3.5.2 Procedures for discontinuation

Subjects who discontinue should always be asked about the reason(s) for their discontinuation and the presence of any AEs. If possible, they should be seen and assessed by an investigator(s). AEs should be followed up; investigational products should be returned by the subject.

Should protocol led dosing be stopped during the study, the investigator(s) will perform the best possible observation(s), test(s) and evaluation(s) as well as give appropriate medication and all possible measures for the safety of the subject. In addition, they will record on the eCRF the date of withdrawal, the reasons, and so on. They will also immediately inform AstraZeneca KK of the withdrawal. Any SAE should be communicated to AstraZeneca KK according to the procedures defined in Section 4.7.1.3.

3.4 Treatments

3.4.1 Identity of investigational products

Formulation, content, and manufacturer of the investigational products are described in Table 2.

Table 2 Investigational products

Investigational products	Formulation and content	Formulation number	Batch number	Manufacturer
D961H capsule 10 mg	Enteric coated capsule containing D961H 11.1 mg with D961H pellets filled into a hard capsule	H 1221-02-01	H 1221-02-01-09	AstraZeneca Sweden Operations Drug Product Supply
D961H capsule 20 mg	Enteric coated capsule containing D961H 22.3 mg with D961H pellets filled into a hard capsule	H 1189-04-01	H 1189-04-01-14	AstraZeneca Sweden Operations Drug Product Supply
D961H capsule placebo	Hard capsules matching with D961H capsule 10 mg and 20 mg	H 0459-06-03	H 0459-06-03-15	AstraZeneca Sweden Operations Drug Product Supply
Omeprazole tablet 10 mg	Enteric tablet containing 10 mg of omeprazole	-	020400	AstraZeneca KK
Omeprazole tablet placebo	Enteric tablet matching with omeprazole 10 mg tablet	-	020010	Astellas Shizuoka Co., Ltd

Packaging of the investigational product:

Fourteen capsules of D961H (10 mg, 20 mg or placebo) will be packed in a blister pack. Fourteen tablets of omeprazole (10 mg or placebo) will be packed in a blister pack, and 3 blister packs will be packed in an aluminum pillow with desiccant. Eighteen blister packs of

D961H capsules and 6 aluminum pillows of omeprazole tablets will be packed in a box for one patient.

3.4.2 Doses and treatment regimens

One D961H capsule and 1 omeprazole tablet will be orally administered once daily after breakfast for 4 weeks, 12 weeks or 24 weeks. However, on the days of dispensing the investigational products, patients must be instructed to take the investigational products at any time on the same day. On the days when EGD are conducted (Visits 3, 5 and 8), patients must be instructed to take the investigational products after the completion of the tests.

Table 3 shows combination of the investigational products for each group.

Table 3 Combination of investigational products

	D20	D10	O10
D961H capsule 20 mg	1 capsule	-	-
D961H capsule 10 mg	-	1 capsule	-
D961H capsule placebo	-	-	1 capsule
Omeprazole tablet 10 mg	-	-	1 tablet
Omeprazole tablet placebo	1 tablet	1 tablet	-

3.4.3 Labeling

Each box will be labelled with name of investigational products, study code, batch number, quantity, expiry, storage conditions, randomisation code, attention, name and address of sponsor, ‘for clinical study use only’.

3.4.4 Storage

All investigational products must be kept in a secure place under appropriate storage conditions. Each box will be labelled with appropriate storage conditions. A description of the appropriate storage is also specified in ‘Procedures for drug storage’.

3.4.5 Accountability

AstraZeneca KK will provide the study documents ‘Procedures for drug accountability’ and ‘Procedures for drug storage’, which describe the specific requirements.

Investigational product will not be distributed to the study site until the contract is concluded between the study site and AstraZeneca KK. The investigational product provided to the study site must only be used for the purpose and the dosage as directed by the clinical study protocol.

The investigator(s) and/or the Investigational Product Storage Manager must instruct the subject to return unused investigational products and used blister packs. The investigator(s)

and/or the Investigational Product Storage Manager must also confirm the number of capsules/tablets returned and recorded in the 'Investigational Product Log'. If there is any discrepancy in the number of capsules prescribed, administered, and returned, the investigator(s) or the study coordinator must confirm the reason with the patient and record it in the eCRF. The Investigational Product Storage Manager and the monitor must confirm that all unused and remaining investigational products are returned to AstraZeneca K.K..

The Investigational Product Storage Manager is responsible for managing the unused investigational products and remaining investigational products returned from the patients from distribution to the study site until the return to AstraZeneca KK.

3.5 Method of assigning subjects to treatment groups

Subjects will be randomised to one of the D20, D10 or O10 groups in the proportion of 1:1:1. A randomisation list will be prepared by the Subject Registration Centre.

The investigator(s) will explain about the study to potential candidates and obtain written informed consent. At the time of informed consent obtained, an Enrolment code will be allocated to each subject at each study site to identify the subject. The Enrolment code (E01XXYYY) is composed of 4 digits (01XX) of centre number and 3 digits (YYY) of consecutive number in order of registration to screening at each study site. For centre number(s), see Supplement A "Investigators and Study Administrative Structure".

Prior to randomisation, the investigator(s) will judged eligibility of the subjects who provided informed consent. After confirming the eligibility of the subject who has given his/her consent, the investigator(s) will enter necessary information in the subject registration form and send it to the Subject Registration Centre by facsimile.

The Subject Registration Centre will check the eligibility of the subject and register the subject. The Subject Registration Centre will allocate a Randomisation code to the subject and send the registration confirmation form containing Randomisation code to the investigator(s) and AstraZeneca KK by facsimile.

After obtaining the registration confirmation form from the Subject Registration Centre, the investigator(s) will start administration of the investigational product to the registered subject following the randomisation code written in the registration confirmation form.

The investigator(s) will keep the registration confirmation form sent from the Subject Registration Centre in the investigator's study file (see Section 7.6.5.1).

Information on the Subject Registration Centre is given below.

[Subject Registration Centre]

Trans Cosmos Inc.

FAX: 0120-266961 (toll free)

(Call toll free 0120-588961 if there is any problem with facsimile machine.)

Opening hours: Monday-Saturday 9:00-18:00 (Closed on Sundays and national holidays, 29th December through 4th January)

The flowchart for subject registration and prescription of the investigational product is shown in Figure 2.

Figure 2 Flow chart for subject registration and prescription of the investigational product

Procedure conducted at the study site | **Procedure conducted at the Subject Registration Centre**

Obtain informed consent from subject
↓
Allocate Enrolment code
↓
Confirm eligibility of subject
↓
Fill out the subject registration form
↓
Fax the subject registration form to the Subject Registration Centre

→

Ensure the subject's eligibility
↓
Allocate Randomisation code
↓
Fax the registration confirmation form to the study site

←

Confirm the subject's registration through the registration confirmation form
↓
Start administration of the investigational product

If a subject discontinues from the study, the enrolment code of the subject will not be reused, and the subject will not be allowed to re-enter the study.

If a Randomisation code is assigned incorrectly, no attempt should be made to remedy the error once investigational products were dispensed. The subject will continue with the allocated randomised code and investigational products. AstraZeneca KK should be notified as soon as the error is discovered. Randomisation of subsequent subjects will continue using the first unallocated Randomisation code in the original sequence.

The investigational product given to individual subjects will be determined by a randomisation schedule. The details of the treatment allocations are described in "Procedures for drug accountability".

3.6 Blinding and procedures for unblinding the study

3.6.1 Methods for ensuring blinding

The study drug is a hard capsule filled with enteric coated D961H pellets. The active ingredient content of D961H capsule 20 mg is different from that of D961H capsule 10 mg but they are indiscriminable in appearance. On the other hand, the comparator is an enteric tablet that contains omeprazole 10 mg as the active ingredient. To maintain the blind feature of these study drugs, the double dummy method is employed in this study. The appearance of D961H capsule placebo and that of omeprazole tablet placebo are indiscriminable from respective active drugs in appearance. Their packages and labels are also indiscriminable from respective active drugs.

It is not planned in this study to conduct interim analysis and data evaluation by the Data monitoring board under blind condition.

3.6.2 Methods for unblinding the study

Individual treatment codes, indicating the treatment randomisation for each randomised subject, will be available to the investigator(s) and the personnel who are independent to the study evaluation at the Drug Safety Department, AstraZeneca KK.

The treatment code must not be broken except in medical emergencies when the appropriate management of the subject necessitates knowledge of the treatment randomisation. The investigator(s) will break the code according to the manual of procedure of emergency key code break provided by AstraZeneca in emergency. AstraZeneca KK retains the right to break the code for SAEs that are unexpected and are suspected to be causally related to an investigational product and that potentially require expedited reporting to regulatory authorities.

Treatment codes will not be broken for the planned analyses of data until all decisions on the evaluability of the data from each individual subject have been made and documented.

3.7 Pre-study, concomitant and post-study treatment(s)

The use of all medications including investigational products and over-the-counter drugs during the study period (from the day of informed consent to the last scheduled visit or withdrawal) must be recorded in the appropriate sections of the eCRF. However, drugs used for pre-treatment of EGD (eg, xylocaine, anticholinergic agents, anti-anxiety agents) will not be recorded in the eCRF.

3.7.1 Allowable concomitant treatments

The following treatments can be used concomitantly during the study period.

- Treatments, which are considered necessary for the subject's safety and well-being
- Drugs used for pre-treatment of EGD (eg, xylocaine, anticholinergic agents, anti-anxiety agents)

3.7.2 Prohibited concomitant treatments

- The following drugs and treatments will be prohibited since these may affect interpretation of results of the investigational products or cause general complications (eg, gastrointestinal bleeding).

[Prohibited concomitant treatments after EGD performed at the screening visit]

- PPI (except for the investigational product)
- H_2 receptor antagonist
- M_1 receptor antagonist
- Hp eradication therapy
- Antacids (treatment with antacids for relief of symptoms is allowed until randomisation)
- Anticholinergics used for GI indications (except for agents used for pre-treatment of EGD such as scopolamine butylbromide)
- Gastrointestinal promotility drugs (eg, metoclopramide)
- Prostaglandin analogs having the indication of peptic ulcer (eg, misoprostol)
- Antineoplastic drugs
- Gastroprotective agents
- Bisphosphonates (eg, etidronate disodium, alendronate sodium)

- Steroids (oral, intravenous, suppository)

[Prohibited concomitant treatments during the treatment period]

During the treatment period, the following drugs as well as those in the above "prohibited concomitant treatments after EGD performed at the screening visit" will be prohibited.

- Drugs that are known to induce drug interaction with D961H and/or omeprazol (eg, HIV proteinase inhibitors including atasanavir sulphate, diazepam [except for pre-treatment of EGD], phenitoin, warfarin, tacrolimus hydrate, digoxin, methyldigoxin, itraconazole, gefitinib, voriconazole)

3.8 Treatment compliance

The study drug is prescribed every 4 weeks in principle, that is, on the scheduled visit of Visits 2-7. The subjects are instructed to return all unused investigational products and used blister packs on the next scheduled visit (Visits 3-8). The quantity of returned investigational product is confirmed to check the compliance status.

If the subject's compliance rate is low due to missing doses, etc, the investigator(s) will instruct the subject to comply with the treatment. Missing doses over 25% will be defined as incompliance.

4. MEASUREMENTS OF STUDY VARIABLES AND DEFINITIONS OF OUTCOME VARIABLES

4.1 Primary variable

The primary variable of this study is presence/absence of recurrence of RE throughout the treatment period according to LA classification.

4.2 Screening and demographic measurements

Before performing the screening test, the investigator(s) must obtain written informed consent from the subject, and then will assess whether the subject meets the eligibility criteria (see Sections 3.3.2 and 3.3.3).

Visit 1 (within 1 week prior to randomisation)

The following items are assessed, measured or conducted in the subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study.

- Demographic data (sex, birth date, race, smoking status, alcohol consumption, height, weight)

- Past medical history (eg, a condition which a patient has had in the past and which has been declared cured), surgical history

- Underlying diseases (diseases or symptoms under treatment [including being controlled by treatment]
- Concomitant therapy/drug
- Physical examinations (see Section 4.7.3)
- Vital signs (blood pressure and pulse rate measured in a sitting position)
- Clinical laboratory tests (haematology, biochemistry, urinalysis)
- Urine pregnancy test (only for premenopausal women of childbearing potential)
- Hp test (IgG antibody)
- Genetic test for CYP2C19 (see Section 4.9)

In the case of subjects whose RE is healed in the preceding study (D961HC00002) and enrolled in this study, the data of the preceding study (D961HC00002) are used as the Visit 1 data. However, the following test is essential to check the eligibility (see Section3.3.3).

- Urine pregnancy test (only for premenopausal women of childbearing potential)

Visit 2 (day of randomisation)

The following items are assessed, measured or conducted in all the subjects.

- AEs (all the SAEs and AEs resulting in discontinuation that occur after informed consent are recorded)
- Underlying diseases (those that are currently under treatment and those that do not correspond to the above mentioned SAEs and AEs resulting in discontinuation)
- Concomitant therapy/drug
- Physical examinations
- Medical interview form (assessment of GERD symptoms at baseline; see Section 4.6.2)

The following item is conducted in the subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study.

- EGD (see Section4.6.1.1)

In the case of subjects whose RE is healed by general treatment and after that give informed consent and are enrolled in this study on the same day, the results of test conducted on

randomisation day are available as the baseline data in this study, these data may be used with the consent of subject even if obtained before informed consent.

In the case of subjects whose RE is healed in the preceding study (D961HC00002) and enrolled in this study, the EGD data obtained at the end of the preceding study (D961HC00002) are used as the baseline data in this study.

4.2.1 Hp test (IgG antibody)

At screening, blood sample (2 mL) will be collected to measure IgG antibody to determine presence/absence of Hp infection. If not performed at screening, the Hp test may be performed at any visit during the period before the subject withdraw or complete the study. Collection of the samples and the measurement will be performed by

4.3 Patient-Reported Outcomes (PRO) (Not applicable)

4.4 Health Economic measurements and variables (Not applicable)

4.5 Pharmacokinetic measurements and variables (Not applicable)

4.6 Efficacy and pharmacodynamic measurement and variables

Table 4 shows efficacy objectives and outcome variables.

Table 4 Efficacy objective and outcome variable

Objective	Outcome variable
Primary objective	
To evaluate the efficacy of D20 for 24 weeks on maintenance of RE in patients with healed RE in comparison with O10 and D10 by assessment of the following.	Presence/absence of recurrence of RE throughout the treatment period according to LA classification
Secondary objective	
To evaluate the efficacy of D20 on maintenance of healed RE in comparison with O10 and D10 by assessment of the following.	Presence/absence of recurrence of RE at Week 4 or before and Week 12 or before according to the LA classification.
To evaluate the efficacy of D20 on GERD symptoms in comparison with O10 and D10 by assessment of the presence/absence and the severity of investigator-reported symptoms at Week 4, 8, 12, 16, 20 and 24.	Presence/absence of each GERD symptom based on the severity assessment for 7 days before the scheduled visits at Week 4, 8, 12, 16, 20 and 24.

4.6.1 Preventive effect of recurrence of RE according to LA classification

4.6.1.1 EGD

The EGD of esophagus, stomach and duodenum is performed on Visits 3, 5 and 8 in all the fasting subjects.

The EGD is performed in fasting condition on Visit 2 as the screening test (baseline) in the subjects whose RE has prospects to be healed by general treatment and enrolled in this study.

In the case of subjects whose RE is healed by general treatment and after that give informed consent and are enrolled in this study on the same day, the results of test conducted on randomisation day are available as the baseline data in this study, these data may be used with the consent of subject even if obtained before informed consent.

In the case of subjects whose RE is healed in the preceding study (D961HC00002) and enrolled in this study, the data at the end of the preceding study (D961HC00002) are used as the EGD data at the time of screening (baseline). Therefore, the EGD on Visit 2 is not necessary.

The EGD is performed by the method usually employed at each medical institution. The drug used for the pre-treatment of EGD is not recorded in eCRF. However, if other drug is used, the name of drug is recorded in eCRF.

The endoscopic findings in esophagus is scored according to the following LA classification and the RE recurrence or not is checked, and they are recorded in eCRF. The presence or absence of esophageal hiatus hernia, Barrett's esophagus (3 cm or longer Barrett's epithelium), esophageal stricture, and gastric and duodenal ulcer is also checked, and the presence or absence of esophageal hiatus hernia is recorded in eCRF.

In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, those with healed RE endoscopically verified on Visit 2 are registered (randomised). However, those detected to have esophageal stricture, Barrett's esophagus (3 cm or longer Barrett's epithelium), and gastric or duodenal ulcer should not be registered (see Section 3.3.3).

LA classification

Grade A: One (or more) mucosal break no longer than 5 mm, that does not extend between the tops of two mucosal folds

Grade B: One (or more) mucosal break more than 5 mm long that does not extend between the tops of two mucosal folds

Grade C: One (or more) mucosal break that is continuous between the tops of two or more mucosal folds, but which involves less than 75% of the circumference

Grade D: One (or more) mucosal break which involves at least 75% of the esophageal circumference

Photo documentation, preferably as colour printouts, is essential as the record of endoscopic images. In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, it is also essential to preserve the EGD photos (to verify that the patient had RE classified into LA classification grade A, B, C or D) within 2 weeks before the start of general treatment with PPIs (see Section 3.3.2) as the source material.

For the central review of the grade of LA classification, all EGD images of all patients allocated the study drugs during the study period will be submitted to AstraZeneca K.K.. The personal information (such as the name and the medical record number) which can specify the patient should be masked before submission to AstraZeneca K.K..

4.6.1.2 Method of assessment

The recurrence of RE is verified when the esophageal finding on Visit 3, 5 or 8 is judged as LA classification grade A, B, C or D. When recurrence of RE is verified on Visit 3 or 5, the subject will discontinue the study at the time point.

4.6.2 Investigator-reported symptoms

On each scheduled visit of Visits 2-8, the subject completes the medical interview form (Appendix D) concerning the overall severity of GERD symptoms in the past 7 days.

The medical interview form is collected after its completion by the subject and stored at each medical institution as the source material of this study.

The investigator(s) checks the medical interview form, assesses each symptom according to the severity classification defined below, and records the result in eCRF.

GERD symptoms

Heartburn: A burning feeling, rising from the stomach or lower part of the chest towards the neck

Acid Regurgitation: Flow of sour or bitter fluid into mouth

Epigastric pain: Central upper abdominal pain

Dysphagia: Difficulties in swallowing

Severity classification

Each symptom will be assessed and classified into either severity given below:

None

Mild: Awareness of symptom, but easily tolerated

Moderate: Discomfort sufficient to cause interference with normal activities

Severe: Incapacitating, with inability to perform normal activities

(Normal activities include eating meals, working, and sleeping.)

4.7 Safety measurements and variables

Table 5 shows safety objectives and outcome variables.

Table 5 Safety objective and outcome variable

Objective	Outcome variable
Secondary objective	
To evaluate the safety and tolerability of D10, D20 and O10 in long-term administration (at Week 24) by assessment of the following.	AEs, laboratory test values, vital signs (blood pressure and pulse rate)

The methods of collection of safety data are shown below.

4.7.1 AEs

4.7.1.1 Definitions

The definitions of AEs, SAEs and other significant adverse events (OAEs) are given below. It is of the utmost importance that all staff involved in the study are familiar with the content of this section. The principal investigator is responsible for ensuring this.

Adverse event

An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. An undesirable medical condition can be symptoms (eg, nausea, chest pain), signs (eg, tachycardia, enlarged liver) or the abnormal results of an investigation (eg, laboratory findings, electrocardiogram). In clinical studies, an AE can include an undesirable medical condition occurring at any time, including run-in or washout periods, even if no study treatment has been administered.

For cases where it could be suspected that a tissue-derived medicine has been contaminated by a pathogen, information about any of the above conditions (including infection) should be collected.

SAE

A SAE is an AE occurring during any study phase, and at any dose of the investigational product, comparator or placebo, that fulfils one or more of the following criteria:

- Results in death
- Is immediately life-threatening
- Requires in-patient hospitalisation or prolongation of existing hospitalisation (including hospitalisation for tests related to AEs), except hospitalisation that has been planned before enrolment.
- Results in persistent or significant disability or incapacity

- Is a congenital abnormality or birth defect
- Is an important medical event that may jeopardise the subject or may require medical intervention to prevent one of the outcomes listed above.

The causality of SAEs (ie, their relationship to study treatment) will be assessed by the investigator(s), who in completing the relevant eCRF must answer "yes" or "no" to the question "Do you consider that there is a reasonable possibility that the event may have been caused by any of the following – study medication – other medication?". For further guidance on the definition of a SAE and a guide to the interpretation of the causality question, see Appendix B.

Note that SAEs that could be associated with any study procedure should also be reported. For such events the causal relationship is implied as "yes".

Other Significant Adverse Events (OAE)

OAEs will be identified by the Study Delivery Team Physician in consultation with the appropriate Global Drug Safety Physician during the evaluation of safety data for the Clinical Study Report. Significant adverse events of particular clinical importance, other than SAEs and those AEs leading to discontinuation of the subject from study treatment, will be classified as OAEs. Examples of these are marked haematological, biochemistry and other laboratory abnormalities, and certain events that lead to intervention (other than those already classified as serious), dose reduction or significant additional treatment. For each OAE, a narrative may be written and included in the Clinical Study Report.

4.7.1.2 Recording of AEs

For AEs spontaneously reported by the subject and/or in response to an open question "Have you had any health problems since the previous visit/during the study period?" asked by the investigator(s) or revealed by observation, only those occurring from initial administration to the last scheduled visit or withdrawal will be recorded at each visit.

Of SAEs and AEs leading to discontinuation of the subject from the study, those occurring during the time from informed consent to the last scheduled visit or withdrawal will be recorded at each visit.

In case any AE occurs, details (such as a description of the event, seriousness, maximum intensity, date of onset, date of resolution, outcome, action taken [investigational products], and causality with the investigational products) should be recorded in the eCRF.

(a) Abnormal findings

The investigator(s) will confirm whether clinically important values and changes from baseline on clinical laboratory or vital signs are observed or not. If any, such findings will be recorded in the specified module of eCRFs. However, if the abnormality meets any of the following criteria, the abnormality should be recorded in eCRF as AE:

- The abnormality results in discontinuation of the study.
- The abnormality meets any criterion for SAE.
- Investigator(s) insists it should be reported as an AE.

If the abnormality is associated with clinical signs and symptoms, the sign/symptom should be recorded in eCRF as AE.

If any abnormal laboratory values and vital signs considered as clinically important values or changes were observed at the time of completion or discontinuation of the study treatment, the investigator(s) will perform additional tests and follow-up until they are recovered or until the investigator(s) consider it is not necessary to be followed. However, there is no need to record the test results in the eCRF. The monitor will record the follow-up results on the monitoring visit report.

(b) EGD findings of disease under the study (RE)

The EGD findings of RE are not reported as the AEs except for those that correspond to the SAE definition (see Section 4.7.1.1). The discontinuation due to recurrence of RE does not correspond to adverse event.

(c) Assessment of causality

The causality of all AEs (i.e., the relationship to study treatment) will be assessed by the investigator(s), who in completing the relevant eCRF must answer "yes" or "no" to the question "Do you consider that there is a reasonable possibility that the event may have been caused by the investigational product?" A guide to the interpretation of the causality question is found in the Appendix B.

Occurrence or aggravation of symptoms due to RE will be recorded on eCRF as AE whose causality with the investigational product is 'None'.

As for SAEs, the causality with the study procedures and concomitant mediations will be judged.

(d) Maximum intensity

Maximum intensity of the reported AEs will be assessed according to the following scale:

- Mild (Awareness of sign or symptom, but easily tolerated)
- Moderate (Discomfort sufficient to cause interference with normal activities)
- Severe (Incapacitating, with inability to perform normal activities)

It is important to distinguish between serious and severe AEs. Severity is a measure of intensity whereas seriousness is defined by the criteria in Section 4.7.1.1. An AE of severe intensity need not necessarily be considered serious. For example, nausea that persists for several hours may be considered severe nausea, but not a SAE. On the other hand, a stroke that results in only a limited degree of disability may be considered a mild stroke but would be a SAE.

(e) Follow-up of AEs (ongoing AEs at the end of/withdrawal from treatment)

The AE information will be recorded in the eCRF until the last scheduled visit or withdrawal.

All AEs unresolved when the study is completed or at the time of withdrawal will be followed until the AE in concern is resolved or the investigator(s) decides that no further follow-up is necessary. More information about such AEs may be requested be AstraZeneca KK.

(f) Overdose

Should an overdose (accidental or deliberate) with the investigational products occur, it must be reported in accordance with the procedures described in Section 9.3, Procedures in case of overdose, regardless of whether the overdose was associated with any symptom or not. All symptoms associated with the overdose should be reported as AEs.

(g) Pregnancy

Should a pregnancy occur after randomisation, it must be reported in accordance with the procedures described in Section 9.4, Procedures in case of pregnancy. Pregnancy in itself is not regarded as an AE unless there is a suspicion that an investigational product may have interfered with the effectiveness of a contraceptive medication.

4.7.1.3 Reporting of SAEs

Investigators and other site personnel must inform appropriate AstraZeneca representatives of any SAE that occurs at his or her centre in the course of the study within 1 day (in this section, within 1 day is defined as “immediately but no later than the end of the next business day”) of when he or she becomes aware of it (initial SAE report). This should apply whether or not the SAE is considered causally related to the investigational product or to the study procedure(s). Wherever possible, this report should be made following the “Reporting Procedure of SAEs using Web-based Data Capture (WBDC) system” described below. The principal investigator must provide detailed information to AstraZeneca in writing within 4 calendar days of the initial report. The Principal Investigator must notify the SAEs in writing to the head of the medical institution immediately.

Follow-up information on SAEs must also be reported to AstraZeneca by the investigator(s) within the same time frames. If a non-serious AE becomes serious, this and other relevant follow-up information must also be provided to AstraZeneca within 1 day as described above.

The following information is required in the initial SAE report to AstraZeneca from the investigator(s); study code, centre number, subject number, AE, seriousness, start date. The following detailed information must be sent to AstraZeneca within 1 day after it becomes available; severity, outcome (including stop date, if available), causality (investigational product and if applicable any other concomitant drug), date when a non-serious AE became serious, withdrawal of study treatment, treatment of AE, concurrent therapy (except for treatment of AE), concurrent medication (including pre-study medication if the causality of the AE cannot be assessed), date of birth, sex, other current illnesses, relevant medical history and if applicable, date and course of death.

If initial or the subsequent reports are made by means other than WBDC, necessary information on any SAEs should finally be entered into eCRF via WBDC system by the investigator(s).

For all SAEs, the AstraZeneca representative will inform the AstraZeneca Drug Safety Department of it by Day 1 and will work with the investigator(s) to compile all the necessary information and ensure that the Drug Safety Department receives a report within 4 calendar days.

In addition AstraZeneca will provide details of any unexpected serious adverse drug reactions or expected fatal or life-threatening serious adverse drug reactions reported with regard to the test product and the control drug if not unblinded in this study or other compound available overseas in which the active ingredient is known to be equivalent to the test product, to the head of the study site, principal investigator and the regulatory agency. The head of the study site must submit a written report to the IRB providing the details of all AE case(s) reported by AstraZeneca.

(a) Reporting Procedure of SAEs using WBDC system

The investigator(s) and other site personnel will access WBDC system and report SAE information by entering it into the relevant eCRF module. Upon entry of the SAE information, an automated email alert will be sent to the designated AstraZeneca representative.

If the system is unavailable, the investigator(s) should take other appropriate measures to provide SAE report to the AstraZeneca representative immediately, recognising that the same reporting time frames still apply. The investigator(s) is responsible for completing the eCRF as soon as the system becomes available again.

4.7.2 Laboratory safety measurements and variables

4.7.2.1 Test items

In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, the test of all the laboratory parameters shown in Table 6 is performed on Visit 1 as the screening test (baseline). On the other hand, the test on Visit 1 is not necessary in the case of subjects whose RE is healed by the initial treatment in the

preceding study (D961HC00002) and enrolled in this study (because the data at the latest visit after Visit 3 [Visit 2, if RE healed at Week 4] of the preceding study [D961HC00002] are used as the screening laboratory test data, and the data at the end of the preceding study [D961HC00002] are used as the baseline laboratory test data).

All the parameters shown in Table 6 are tested in all the subjects on Visits 3, 5 and 8 (at Week 4, 12 and 24).

The test items are shown below. See Table 7 for the collected amount of blood.

Table 6 The items of laboratory safety

	Items
Biochemistry test:	AST (GOT), ALT (GPT), γ-GTP, ALP, LDH, total bilirubin, total protein, albumin, BUN, creatinine, uric acid, sodium, potassium, total cholesterol, neutral fat, CK (CPK)
Haematology test:	Red blood cell count, hemoglobin, hematocrit, white blood cell count, leukocyte differential count (neutrophil, eosinophil, basophil, lymphocyte, monocyte), platelet count
Urinalysis (qualitative)*:	Occult blood, protein, glucose

* About 10 mL of urine is collected and tested by the test paper method.

4.7.2.2 Methods of assessment

During the study period, will be designated as a central laboratory for this study in order to assure that the standardisation of the assessment and clinically significant comparison between the 3 treatment groups will be accomplished.

In the case of subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study, the Visit 1 laboratory tests are performed in all of them who have given consent and the values are determined at the central laboratory within 1 week before randomisation. If the results of test conducted within 2 weeks prior to randomisation at the laboratory test department of each participating medical institution are available, the eligibility may be checked using these test values even if obtained before informed consent. However, baseline clinical laboratory tests must be conducted at the central laboratory within 1 week prior to randomisation.

In the case of subjects whose RE is healed by the initial treatment in the preceding study (D961HC00002) and enrolled in this study, the data determined at the central laboratory at the latest visit after Visit 3 (Visit 2, if RE healed at Week 4) of the preceding study (D961HC00002) are used as the screening laboratory test values, and the data determined at the central laboratory at the end of the preceding study (D961HC00002) are used as the baseline laboratory test values.

If the investigator(s) considers it clinically necessary (example: in the case of abnormal or severe adverse event), additional blood samples may be taken.

For the blood samples measured by , the central laboratory will supply the materials (eg, test tubes, labels) necessary for collection of the blood samples, storage, and transfer. Methods of collection of the blood sample, processing, and transfer are described in the manual that will be provided to each study centre by AstraZeneca KK..

See Section 4.7.1.2 for details of methods for recording and reporting AEs based on the findings of clinical laboratory values.

4.7.3 Vital signs and physical examination

(a) Vital signs

At all visits except for Visit 2, blood pressure/pulse rate will be measured in a sitting position.

(b) Physical examinations

At all visits, general appearance, lymph node, thyroid gland, cardiovascular system, lung, abdomen, musculoskeletal/extremities, and reflex will be examined. Presence/absence of deterioration or new findings from the baseline (Visit 2) will be checked, and if relevant findings are found, they will be recorded as AEs in the eCRF.

4.8 Volume of blood sampling and handling of biological samples

The total volume of blood that will be drawn from each subject in this study is as follows:

Table 7 Volume of blood to be drawn from each subject

Assessment		Sample volume (mL)	No. of samples*	Total volume (mL)*
Characteristic of patient	Hp test	2	1 (0)	2 (0)
Safety	Biochemistry	4	4 (3)	16 (12)
	Haematology	2	4 (3)	8 (6)
Genotyping	CYP2C19	2	1 (0)	2 (0)
Total				28 (18)

* The values in brackets are the number of samples and total volume of blood in the case of subjects whose RE is healed by the initial treatment in the preceding study (D961HC00002) and enrolled in this study. Since no test is performed on Visit 1 in these subjects, the frequency of scheduled tests is less in comparison with that in the subjects whose RE has prospects (or was confirmed) to be healed by general treatment and enrolled in this study.

4.8.1 Analysis of biological samples

4.8.1.1 Biochemistry samples

The analyte stability limits defined by will be applied to all analyses performed on behalf of AstraZeneca KK. will not analyse samples that fall outside these stability limits. The results will not be reported if found to have been derived from a sample that fell outside these stability limits. The standards of procedure followed by may be amended in accordance with its Standard Operating Procedures.

If chooses to sub-contract the analytical work to another laboratory, must assure itself and provide assurance to AstraZeneca KK that the other laboratory will apply defined stability limits to all analyses performed on behalf of AstraZeneca KK. Samples falling outside these limits must not be analysed or data reported.

4.9 Genetic test

4.9.1 Purpose of genetic test

The purpose of the genetic research is to investigate the genotype of CYP2C19, a metabolising enzyme of D961H known to have two genotypes, namely 'EM' (homo- and hetero-types) and 'poor metaboliser'. Since the changes in the blood D961H concentrations showed different tendency between the two metabolisers, and the difference is considered to affect the efficacy of D961H, they will be examined (see Appendix C for criteria for evaluation of phenotypes).

4.9.2 Collection of samples for genetic research

Subjects will provide a blood sample of 2 mL at screening to be used for genetic test of cytochrome P450 subtype CYP2C19, a metabolising enzyme of D961H.

will carry out collection of the samples and measurement.

Genotype is a stable parameter, therefore if for any reason the blood sample is not drawn at screening, it may be taken at any visit until the discontinuation or completion of the study. It is preferable that the blood sample for genotype will be collected at the same time when blood samples for other assessment are collected.

Procedures for sample collection and shipment must be followed as described in Appendix C.

4.9.3 Storage and coding of samples for genetic test

Special attention is required for conducting a genetic test. The following items should be obeyed to conduct a genetic test and explained to the subjects at the time informed consent is provided:

- Written informed consent to a genetic test must be provided by each subject.
- From the aspect of this study design, implementation of a genetic test is a requirement for the subject to participate in the study.
- From the aspect of this study design, personnel involved in the study at the study centres and AstraZeneca KK will have knowledge of genetic information on the subjects based on the genetic test results.
- Samples for the genetic test to be sent to the laboratory will not be labelled with subject identifiers so that the information on the subject will not be revealed to any other parties.
- Samples of the subject who is not enrolled in the study will be destroyed immediately by the study site or .
- If the genetic test for the sample of the subject who is not enrolled in the study was completed, the results of the test and the records will be destroyed immediately by .
- In the case the subject in concern wishes a release of the genetic test results in the informed consent form, the result will be disclosed to the subject via investigator(s) after the database of this study is locked. However, the result will be disclosed to the subject immediately even before the database is locked only when the subject requests to do so during the study period.
- All samples collected for a genetic test will be used only for CYP2C19 genotyping and will be destroyed immediately by
after completion of the genetic test on CYP2C19.

5. DATA MANAGEMENT

Data will be entered in the WBDC system at the study site. Trained study personnel will be responsible for entering data on the observations, tests and assessments specified in the protocol into the WBDC system and according to the eCRF Instructions. The eCRF Instructions will also provide the study site with data entry instructions. Data entered in the WBDC system will be immediately saved to a central database and changes tracked to provide an audit trail. AstraZeneca KK will make an inquiry to the investigator(s) for missing, unreal, or conflict data that have been entered using the WBDC system. When data have been entered, reviewed and edited, and Source Data Verification performed, the principal investigator will be notified to sign the eCRF electronically as per the agreed project process and data will be locked to prevent further editing. A copy of the eCRF will be archived at the study site. Quality control procedures will be applied to each stage of the data handling to ensure that all data are reliable and have been processed correctly.

6. STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE

6.1 Statistical evaluation – general aspects

A comprehensive Statistical Analysis Plan will be prepared before unblinding of the data. A significant level of $p<0.05$ (two-sided) will be used, in principle, for statistical tests and interval estimation.

All statistical analyses in this study will be performed by Statistics and Programming Department of AstraZeneca KK using the SAS software.

6.2 Description of outcome variables in relation to objectives and hypotheses

6.2.1 Primary outcome variables

The primary variable of this study is the presence/absence of recurrence of RE throughout the treatment period (from the randomisation to the treatment completion) according to LA classification.

6.2.2 Secondary outcome variables

The secondary outcome variables of this study are as follows.

Efficacy

- Presence/absence of recurrence of RE at Week 4 or before and 12 or before according to LA classification.
- Presence/absence of each GERD symptom based on the severity assessment for 7 days before the scheduled visits at Week 4, 8, 12, 16, 20 and 24.

Safety

- AEs
- Laboratory test values
- Vital signs (blood pressure and pulse rate)

6.3 Description of analysis sets

For the efficacy data analysis, two analysis sets, that is, the full analysis set (FAS) and per protocol set (PPS) will be used. The FAS will be used as the primary efficacy analysis set. Both FAS and PPS will be used for the analysis of the primary variable but only FAS will be used in the analysis of secondary efficacy variables.

All the randomised subjects with healed RE endoscopically verified before the start of administration and who have taken at least one dose of study drug will be included in the FAS. Of the subjects included in the FAS, those who have no major protocol violations or deviations that may affect the efficacy assessment and those who have a good compliance with the study will be included in the PPS. The population excluding subjects who are declared not to have healed RE by the central evaluation committee (see Section 6.7) before dosing will be also evaluated. In this analysis, the evaluation of the central evaluation committee for the reccurence of RE after dosing will be used.

All the analysis sets will be determined before unblinding of the data.

All the subjects who have taken at least one dose of study drug and whose data after the treatment start are available will be included in the safety analysis set. All the safety analyses will be conducted using the safety analysis set.

6.4 Method of statistical analysis

6.4.1 Primary outcome variables

The recurrence of RE verified by EGD is handled as an event. The time to event from the starting day of study drug administration will be analysed by Kaplan-Meier method and Kaplan-Meier plot of non-recurrence rate will be prepared for each dose group. The subject without recurrence until the end of study will be treated as censored at the timing of the last EGD. The non recurrence rate-time curves between the D20 group and O10 group and between D20 group and D10 group will be compared by a Log-rank test. If possible, the median value of the time to event will be obtained for each group by Kaplan-Meier method.

The proportion of subjects without the recurrence of RE verified by EGD (no-recurrence cases) in the analysis set is defined as the no-recurrence rate of RE. The no-recurrence rate at Week 24 and its two-sided 95% confidence interval will be estimated for each group using the prepared Kaplan-Meier plot. As the secondary analysis, the no-recurrence rate at Week 24 is also calculated by the following method.

The subjects without the recurrence of RE verified by EGD at Week 24 or those who discontinued the study without the recurrence before the EGD at Week 24 are handled as the no-recurrence cases. The no-recurrence rate at Week 24 and its 95% confidence interval will be calculated for each dose group. The no-recurrence rate in each subgroup at Week 24 and its two-sided 95% confidence interval are calculated by group for the following factors based on the corresponding calculation method.

- Sex
- Age (<65 years old, ≥65 years old)
- Presence or absence of Hp infection
- CYP2C19 genotype (homo EM, hetero EM, PM)

6.4.2 Secondary outcome variables

In the analyses for the secondary outcome variables, only FAS will be used for the efficacy variables and the safety analysis set will be used for all safety variables.

6.4.2.1 Efficacy

Presence/absence of recurrence of RE at Week 4 or before and Week 12 or before according to the LA classification

The no-recurrence rate in Week 4 and 12 will be obtained by the 2 calculation methods as in the case of primary variable, and the data will be analysed as in the case of primary variable.

Presence/absence and severity of GERD symptoms assessed by the investigator(s)

Four GERD symptoms (heartburn, acid regurgitation, epigastric pain, dysphagia) will be assessed for each patient at pre-dose and each timepoint at post-dose on the 4-point scale 'None', 'Mild', 'Moderate' and 'Severe'. For each of the 4 symptoms, a cross table of the severities at pre-dose and each time point of post-dose will be prepared. For patients who have 'None' for a symptom at pre-dose, the percentage of the patients who have the symptom at the subsequent time points will be calculated at each time point of post-dose, and for patients who have a symptom at pre-dose, the percentage of the patients whose symptoms are resolved will be calculated at each time point of post-dose.

6.4.2.2 Safety variables

AEs

All AEs will be classified by system organ class and by preferred term using MedDRA and those occurred at baseline and after administration of the investigational products will be summarised in separate lists. AEs occurred after administration of the investigational products will be classified by system organ class and by preferred term using MedDRA independently for each treatment group. Data on drug-related AEs will be collected in the same manner, as required. The number of subjects who developed AEs, drug-related AEs, SAEs, and AEs led to withdrawal from the study will be summarised for each treatment group, together with the total number of AEs, drug-related AEs, SAEs and AEs leading to withdrawal from the study.

Clinical laboratory values

Quantitative data of clinical laboratory values will be summarised using descriptive statistics and qualitative data will be summarised using frequency table for each treatment group at each timepoint.

Vital signs

Quantitative data of vital signs will be summarised for each treatment group at each timepoint using descriptive statistics.

6.5 Determination of sample size

The sample size for this study was calculated in order to show that the non-relapse rates at Week 24 for D20 would be superior to that for D10 and O10. The non-relapse rates for D20 and D10 were assumed to be 80% and 65%, respectively from the results of previous overseas studies (SH-QBE-0014/177 and SH-QBE-0015/178) and the non-relapse rate for O10 was assumed to be 60% from the result of the Japanese RE maintenance study (RO-1). To have 80% power to detect a difference of the cumulative non-relapse rates between D20 and D10 based on a log-rank test, with 0.025 two-sided significant levels, 172 subjects who complete the study are needed for each treatment group. Assuming that 5% subjects will withdraw before completing the 24-week treatment, 180 patients will be randomised for each dose group in the study (in total 540 patients in 3 groups).

6.6 Interim analyses (Not applicable)

6.7 Central evaluation committee

For this study, a central evaluation committee that consists of experts in the gastrointestinal area will be established to confirm the rationale for judgement by the investigator(s) based on the EGD images.

The board will review all EGD images of all patients allocated the study drugs during the study period as needed and report the results of the review to AstraZeneca K.K..

Time to hold the meeting and the responsibilities of the board members will be determined separately.

7. STUDY MANAGEMENT

7.1 Monitoring

Before the first subject is entered into the study, a representative of AstraZeneca will visit the investigational study site to:

- Determine the adequacy of the facilities
- Discuss with the investigator(s) (and study coordinators) their responsibilities with regard to protocol adherence, and the responsibilities of AstraZeneca or its representatives. This will be documented in a Clinical Study Agreement between AstraZeneca and the principal investigator
- Discuss the specific requirements of the genetic test with the investigator(s) (and study coordinators)

During the study, a monitor from AstraZeneca or company representing AstraZeneca will have regular contacts with the study site, including visits to:

- Provide information and support to the investigator(s)
- Confirm that facilities remain acceptable
- Confirm that the investigator(s) and study coordinators are adhering to the protocol, that data are being accurately recorded in the eCRFs, and that investigational product accountability checks are being performed
- Perform source data verification (a comparison of the data in the eCRFs with the subject's medical records at the hospital or practice, and other records relevant to the study). This will require direct access to all original records for each subject (eg, clinic charts).
- Perform source verification of the genetic consent of participating subjects and ensure that the investigational team is adhering to the specific requirements of this genetic test

The monitor or another AstraZeneca representative will be available between visits if the investigator(s) or study coordinators at the centre need information and advice.

Source data are any data generated as a result of the subject's inclusion in the study (including run-in and/or follow up related to the study) and includes all related medical examinations and other records. Original data recorded on the eCRFs and regarded as source data are specified in the Clinical Study Agreement between AstraZeneca and the principal investigator.

7.1.1 Direct access to source data in Japan

The head of the study site and the investigator(s) should cooperate for monitoring and audit by AstraZeneca, and accept inspection by the IRB or regulatory authorities. All study documents such as raw data should be open for direct access to source data at the request of the monitor and the auditor representing AstraZeneca, the IRB, or regulatory authorities.

The monitor(s) will verify data from the eCRFs against source data to ensure accuracy and completeness of documentation. When the data in the eCRF are changed or modified, the monitor will confirm the amended part (and the reason for amendment) with the investigator(s).

7.2 Audits and inspections

Auditor representing AstraZeneca, a regulatory authority, an IRB may visit the centre to perform audits or inspections, including source data verification. The purpose of an AstraZeneca audit or inspection is to systematically and independently examine all study-related activities and documents to determine whether these activities were conducted, and data were recorded, analysed, and accurately reported according to the protocol, regulatory requirements described in Section 8.2 and ethical principles.

All study data may undergo a reliability review and onsite-GCP inspection by the regulatory authorities.

7.3 Training of staff

The principal investigator will maintain a record of the sub-investigators and all investigational staff involved in the study (medical, nursing and other staff). He or she will ensure that appropriate training relevant to the study is given to all of sub-investigators and these staff that any new information of relevance to the performance of this study is forwarded to the staff involved.

Before the first subject is entered into the study, the investigator(s) and investigational staff will be trained to use the WBDC system by AstraZeneca personnel or delegates.

Before the first subject is entered into the study the investigational staff will have an opportunity to discuss the procedures associated with the collection of blood samples, extraction of DNA and genetic tests with AstraZeneca personnel. The ethical considerations specific to genotyping and the importance of the informed consent process will be clarified. The requirements for the collections of the subjects' samples will also be clarified.

7.4 Changes to the protocol

Study procedures will not be changed without the mutual agreement of the Co-ordinating Investigator and AstraZeneca.

If it is necessary for the study protocol to be amended, the amendment must be submitted to the head of the study site and be approved by IRB. If applicable, AstraZeneca KK should submit a notification to the regulatory authority before it is implemented.

If a protocol amendment requires a change to a particular centre's Informed Consent Form, then AstraZeneca and IRB must be notified. Approval of the revised Informed Consent Form by AstraZeneca and by the IRB is required before the revised form is used.

AstraZeneca will distribute amendments and if applicable the amended protocol to each principal investigator and the head of study site, who in turn is responsible for the distribution of these documents to IRB, and the principal investigator will distribute them to the sub-investigator and study coordinator. The distribution of these documents to the regulatory authority will be handled according to local practice.

7.5 Study agreements

The principal investigator at each centre must comply with all the terms, conditions, and obligations of the Clinical Study Agreement for this study. In the event of any inconsistency between this Clinical Study Protocol and the Clinical Study Agreement, the Clinical Study Protocol shall prevail.

7.6 Study timetable and end of study

Before a subject's enrolment in the study and any study-related procedures are undertaken the following should be fulfilled:

- Signed Clinical Study Protocol and other agreements between AstraZeneca and the principal investigator/Study Site.
- Approval of the study in written form by the IRB
- Head of study site Approval Letter
- Approval of the study, if applicable, by the regulatory authority.

7.6.1 Planned duration of the study

Study period: January 2008 – September 2009

Registration period: January 2008 – March 2009

7.6.2 Discontinuation or suspension of the whole study programme

If AstraZeneca KK decides to prematurely terminated or suspended the study, the principal investigator, the head of the study site, and regulatory authorities must receive written notification of the reasons for the premature termination.

The investigator(s) will immediately notify the decision to the subjects, give appropriate medical treatment; take necessary measures, and record treatment or measures provided on the source documents.

7.6.3 Completion of the study

Upon completion of the study, the principal investigator will report in writing the completion of the study as well as the summary of the results to the head of study site in accordance with the institution's rules. The head of study site who is informed of the termination by the principal investigator will provide a written notification of the results to the IRB and AstraZeneca.

7.6.4 Deviations from the protocol and the recording

The investigator(s) must not deviate from or make any changes to the protocol without documented agreement between the principal investigator and AstraZeneca KK or the IRB approval based on its deliberations.

The investigator(s) will record all deviations from the protocol. The principal investigator will report details of the deviation and its reason to AstraZeneca KK, and retain a copy of the report.

The principal investigator should submit a report to AstraZeneca KK and the head of the study site (and the IRB via the head of the study site), to notify any change that may give a significant impact on the conduct of the study or increase a risk to the patient.

The investigator(s) may deviate from or make a change to the protocol without documented agreement between the principal investigator and AstraZeneca KK or the IRB approval, only in the event of a medical emergency, e.g. it is only way to avoid an emergency risk to the patient. In such case, the principal investigator must notify details of the deviation or change, the reason, and a proposed revision in the protocol if required, to AstraZeneca KK and the head of the study site (and IRB via the head of the study site) as soon as possible, in order to obtain their approval. A certificate of approval by the head of the study site as well as AstraZeneca KK should be obtained via the head of the study site.

7.6.5 Archiving of records at the study centre

7.6.5.1 Filing of study related materials

AstraZeneca KK will provide the principal investigator with a file in which to organise and retain all study-related documents. All study documents (including letters from AstraZeneca KK) should be retained in this file by the principal investigator. The monitor will regularly check the file to ensure that all relevant documents are retained. The contents of the file may be audited/inspected by AstraZeneca KK's auditor, regulatory authorities, or IRB.

7.6.5.2 Archiving period

The study site (and the principal investigator) will retain the essential documents specified in the GCP (e.g., source document such as medical records, contract, signed consent form) until the day shown below, whichever is the latest.

- The day when a manufacturing/marketing approval for the investigational product is obtained
- At least 3 years have elapsed since the formal discontinuation of clinical development of the investigational product if the development is discontinued
- At least 3 years have elapsed since the early termination or discontinuation of the study

However this is not always applied to items that are not preservable such as blood samples.

In the event of any inconsistency between the above-mentioned contents and the contract with the study site, the contract shall prevail. These essential documents should be retained for a longer period however if needed by AstraZeneca KK, and the specific period and method of retention will be separately discussed between the study site and AstraZeneca KK. AstraZeneca KK should notify the head of the study site in writing when the study related records are no longer needed.

The records should be managed by a responsible person appointed by the head of the study site.

8. ETHICS

8.1 Ethics review

The final study protocol, including the final version of the Informed Consent Form, and eCRF must be approved or given a favourable opinion in writing by an IRB as appropriate. The IRB must approve all advertising used to recruit patients for the study, if planned. The head of the medical institute must submit a copy of the written approval and documents describing decision of the head of the study centre along with the institutions related to the approval to AstraZeneca KK. A valid contract between the medical institution and AstraZeneca KK must be signed before the investigator(s) can enrol any patient into the study.

The head of the study site is responsible for informing the IRB of any amendments to the protocol in accordance with Japanese GCP. The protocol must be re-approved by the IRB annually. The principal investigator must submit progress reports to the IRB via the head of the study site at the time of the protocol re-approval.

Where there is a genetic test, approval must be obtained for this genetic test and the associated genetic informed consent from the IRB. The head of the study centres must submit a copy of the approval by the IRB and documents describing the instructions based on the contents approved and decisions by the head to AstraZeneca KK before conducting a genetic test.

8.2 Ethical conduct of the study

The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki, 'Good Clinical Practice for Trials on Drugs (MHLW Ordinance No. 28, 27 March 1997), its partially revised and their related notifications and the AstraZeneca policy on Bioethics.

Since this study includes genetic tests, special precautions are taken as described in Section 4.9.

8.3 Informed consent

The investigator(s) at each centre will ensure that the subject is given full and adequate oral and written information about the nature, purpose, possible risk and benefit of the study. Subjects must also be notified that they are free to discontinue from the study at any time. The subject should be given the opportunity to ask questions and allowed time to consider the information provided.

The subject's signed and dated informed consent must be obtained before conducting any procedure specifically for the study.

The principal investigator(s) must store the original, signed Informed Consent Form. A copy of the signed Informed Consent Form must be given to the subject.

The genetic test is mandatory and the subject cannot participate in the main study without participating in the genetic component. To participate in the study the subject must sign and date both the consent form for the main study (non-genetic components of the study) and the genetic component of the study. Copies of both signed and dated consent forms must be given to the subject and the original filed at the study centre. The investigator(s) is responsible for ensuring that consent is given freely and that the subject understands that they may freely discontinue the genetic aspect of the study at any time (if the subject withdraw his/her consent to the genetic test, the entire study will be terminated for the subject).

If modifications are made to the informed consent form, the new version has to be approved by AstraZeneca KK and an IRB.

8.4 Subject data protection

The Informed Consent Form will explain that study data will be stored in a computer database, maintaining confidentiality in accordance with Japanese data legislation. All data computer processed by AstraZeneca KK will be identified by enrolment code.

The Informed Consent Form will also explain that for data verification purposes, authorised representatives of AstraZeneca KK, a regulatory authority, an IRB may require direct access to parts of the hospital or practice records relevant to the study, including subjects' medical history.

All data protection and confidentiality principles, described in the main study protocol, are also applicable to this genetic test.

In implementation of this genetic test, all relevant information should be recorded in the clinical study records (and electronic data).

The results of the genetic test will be informed to AstraZeneca KK and the investigator(s) after the database is locked. In the case the subjects wished to be informed of the test results, the relevant information will be disclosed to the subject after the database is locked. However, the result will be disclosed to the subject immediately even before the database is locked only when the subject requests to do so during the study period.

9. PROCEDURES IN CASE OF EMERGENCY, OVERDOSE OR PREGNANCY

9.1 AstraZeneca emergency contact procedure

In the case of a medical emergency you may contact the Monitor. If the Monitor is not available, contact the Study Delivery Team Leader. If the Study Delivery Team Leader is not available, contact the Study Delivery Team Physician shown below.

Role in the study	Name	Address & telephone number
Monitors	See Supplement A	
Study Delivery Team Leader		
Study Delivery Team Physician		

9.2 Procedures in case of medical emergency

The principal investigator(s) is responsible for ensuring that procedures and expertise are available to handle medical emergencies during the study. **A medical emergency usually constitutes an SAE and should be reported as such, see Section 4.7.1.1.**

9.3 Procedures in case of overdose

In this study, overdose is defined as 6 capsules or more of D961H per day or 6 tablets or more of omeprazole per day.

No antidote is known for D961H and omeprazole. Omeprazole has a low acute toxicity. Nausea, vomiting, dizziness, abdominal pain, diarrhoea and headache have been reported.

In case of a known or suspected overdose, symptomatic treatment should be given and general statement including vital signs should be monitored.

Procedures followed in case of overdose will be as follows:

- An overdose with associated SAEs should be recorded as the SAE diagnosis/symptoms on the relevant AE forms in the eCRFs (See Section 4.7.1.3). In addition, the overdose should be recorded on the relevant overdose module in the eCRF.

- An overdose with associated non-serious AEs should be recorded as the AE diagnosis/symptoms on the relevant AE forms in the eCRFs. In addition, the overdose should be recorded on the relevant overdose module in the eCRF.

- An overdose without associated symptoms should not be recorded as an AE in the eCRFs. The overdose should be recorded on the relevant overdose module in the eCRF.

9.4 Procedures in case of pregnancy

Pregnancy itself is not regarded as an AE unless there is a suspicion that the investigational product under study may have interfered with the effectiveness of a contraceptive medication. However, the outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or congenital abnormality) must be followed up and documented even if the subject was discontinued from the study.

All reports of congenital abnormalities/birth defects are SAEs. Spontaneous miscarriages should also be reported and handled as SAEs. Elective abortions without complications should not be handled as AEs. All outcomes of pregnancy must be recorded on the relevant pregnancy module in the eCRF.

10. REFERENCES

Befrits R, Sjöstedt S, Odman B, Sörngård H, Lindberg G. Curing Helicobacter pylori infection in patients with duodenal ulcer does not provoke gastroesophageal reflux disease. Helicobacter. 2000;5:202-5.

Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med. 1996;334:1018-22.

Labenz J, Blum AL, Bayerdörffer E, Meining A, Stolte M, Börsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology. 1997;112:1442-7.

Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, J P Galmiche JP, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut 1999;45:172-80

Moayyedi P, Bardhan C, Young L, Dixon MF, Brown L, Axon AT. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology. 2001;121:1120-6.

Pace F, Negrini C, Wiklund I, Rossi C, Savarino V. Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:349-56.

Sugiyama T: Is eradication the cause of GERD onset after H. pylori eradication? - Verification of Labenz' report -. Journal of the Japanese Society for Helicobacter Research. 2003; 4:25-7.

The Japanese Society for Helicobacter Research: H. pylori infection diagnosis and treatment guideline - revised edition -. February 2003. http://www.jshr.jp/Japanese/06 _gakkaishi/index.html

Clinical Study Protocol: Appendix A	
Drug Substance	D961H
Study Code	D961HC00006
Appendix Edition Number	1
Appendix Date	

Appendix A
Signatures

ASTRAZENECA SIGNATURE(S)

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg once daily oral administration with omeprazole 10 mg and D961H 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

---

I agree to the terms of this study protocol.

This document contains confidential information, which should not be copied, referred to, released or published without written approval from AstraZeneca. Investigators are cautioned that the information in this protocol may be subject to change and revision.

ASTRAZENECA SIGNATURE(S)

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg once daily oral administration with omeprazole 10 mg and D961H 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

---

I agree to the terms of this study protocol.

This document contains confidential information, which should not be copied, referred to, released or published without written approval from AstraZeneca. Investigators are cautioned that the information in this protocol may be subject to change and revision.

ASTRAZENECA SIGNATURE(S)

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg once daily oral administration with omeprazole 10 mg and D961H 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

---

I agree to the terms of this study protocol.

This document contains confidential information, which should not be copied, referred to, released or published without written approval from AstraZeneca. Investigators are cautioned that the information in this protocol may be subject to change and revision.

SIGNATURE OF PRINCIPAL INVESTIGATOR

A multicentre, randomised, double-blind, parallel-group, comparative study to compare the efficacy and safety of D961H 20 mg once daily oral administration with omeprazole 10 mg and D961H 10 mg once daily oral administration in maintenance treatment in patients with healed reflux esophagitis

---

I will conduct the study according to the procedures specified herein, and according to the principles of Good Clinical Practice (GCP) and local regulations. I agree this after careful reviews of the protocol and the sample of the case report form.

Centre No.:

Signature:

_____ _____

Date
(Day Month Year)

This document contains confidential information, which should not be copied, referred to, released or published without written approval from AstraZeneca. Investigators are cautioned that the information in this protocol may be subject to change and revision.

Clinical Study Protocol: Appendix B	
Drug Substance	D961H
Study Code	D961HC00006
Appendix Edition Number	1
Appendix Date	

Appendix B
Additional Safety Information

FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS ADVERSE EVENT (SAE)

Life threatening

'Life-threatening' means that the subject was at immediate risk of death from the AE as it occurred or it is suspected that use or continued use of the product would result in the subject's death. 'Life-threatening' does not mean that had an AE occurred in a more severe form it might have caused death (eg, hepatitis that resolved without hepatic failure).

Hospitalisation

Out-patient treatment in an emergency room is not in itself a serious AE, although the reasons for it may be (eg, bronchospasm, laryngeal oedema). Hospital admissions and/or surgical operations planned before or during a study are not considered AEs if the illness or disease existed before the subject was enrolled in the study, provided that it did not deteriorate in an unexpected way during the study.

Important medical event or medical intervention

Medical and scientific judgement should be exercised in deciding whether a case is serious in situations where important medical events may not be immediately life-threatening or result in death, hospitalisation, disability or incapacity but may jeopardize the subject or may require medical intervention to prevent one or more outcomes listed in the definition of serious. These should usually be considered as serious.

Simply stopping the suspect drug does not mean that it is an important medical event; medical judgement must be used.

Examples of such events are:

- Angioedema not severe enough to require intubation but requiring iv hydrocortisone treatment
- Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring treatment with N-acetylcysteine
- Intensive treatment in an emergency room or at home for allergic bronchospasm
- Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or convulsions that do not result in hospitalisation
- Development of drug dependency or drug abuse.

A GUIDE TO INTERPRETING THE CAUSALITY QUESTION

The following factors should be considered when deciding if there is a "reasonable possibility" that an AE may have been caused by the drug.

- Time Course. Exposure to suspect drug. Has the subject actually received the suspect drug? Did the AE occur in a reasonable temporal relationship to the administration of the suspect drug?

- Consistency with known drug profile. Was the AE consistent with the previous knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same pharmacological class? OR could the AE be anticipated from its pharmacological properties?

- Dechallenge experience. Did the AE resolve or improve on stopping or reducing the dose of the suspect drug?

- No alternative cause. The AE cannot be reasonably explained by another aetiology such as the underlying disease, other drugs, other host or environmental factors.

- Rechallenge experience. Did the AE reoccur if the suspected drug was reintroduced after having been stopped? AstraZeneca would not normally recommend or support a rechallenge.

- Laboratory tests. A specific laboratory investigation (if performed) has confirmed the relationship?

A "reasonable possibility" could be considered to exist for an AE where one or more of these factors exist.

In contrast, there would not be a "reasonable possibility" of causality if none of the above criteria apply or where there is evidence of exposure and a reasonable time course but any dechallenge (if performed) is negative or ambiguous or there is another more likely cause of the AE.

In difficult cases, other factors could be considered such as:

- Is this a recognised feature of overdose of the drug?

- Is there a known mechanism?

Ambiguous cases should be considered as being a "reasonable possibility" of a causal relationship unless further evidence becomes available to refute this. Causal relationship in cases where the disease under study has deteriorated due to lack of effect should be classified as no reasonable possibility.

Clinical Study Protocol: Appendix C	
Drug Substance	D961H
Study Code	D961HC00006
Appendix Edition Number	1
Appendix Date	

Appendix C
Handling of samples for genetic analysis

1. COLLECTION AND SHIPPING OF SAMPLES FOR GENETIC ANALYSIS

1. After obtaining consent from the subject for genetic analysis of CYP2C19, the study centre will take a blood sample for the analysis of CYP2C19 genotype from the subject within the specified period. When the study centre completes the blood sampling from the subject for the analysis of CYP2C19, the study centre will request to collect the sample.

2. Before a blood sample is taken, the person in charge of blood drawing (or responsible person) will confirm that the subject gave consent to genetic analysis of CYP2C19. After the confirmation, venous blood of about 2 mL will be taken from the subject into a vacuum tube containing heparin sodium provided by , which will be gently rotated several times to mix completely. The person in charge of blood drawing (or responsible person) will enter a) E-code and b) blood sampling date on the label of the tube, and will put the tube into a plastic bag to prevent leakage of blood when the tube is broken.

3. A request form for the analysis prepared by will be entered with a) E-code and b) blood sampling date, inserted into the plastic bag mentioned in the above 2nd paragraph together with the sample, and stored in a refrigerator (at around 4 degrees centigrade) until collects it.

4. will collect the blood samples, extract DNA from the samples, analyze CYP2C19 genotype and store the DNA samples in a secure environment in a DNA storage place within After completion of this study, the DNA samples will be destroyed according to the standard procedures of n, without being used for any other purposes.

2. CRITERIA FOR JUDGEMENT OF PHENOTYPE

The phenotype will be judged using Table 1.

Table 1 CRITERIA FOR JUDGEMENT OF PHENOTYPE

		*2 (exon 5)		
		*1/*1	*1/*2	*2/*2
*3 (exon 4)	*1/*1	EM	EM	PM
	*1/*3	EM	PM	*PM*
	*3/*3	PM	*PM*	*PM*

EM: Extensive Metabolizer
PM: Poor Metabolizer
PM: Poor Metabolizer (with no detected case ever)
□: Homotype

3. COMPANY IN CHARGE OF GENETIC ANALYSIS AND SAMPLE COLLECTION

Clinical Study Protocol: Appendix D	
Drug Substance	D961H
Study Code	D961HC00006
Appendix Edition Number	1
Appendix Date	

Appendix D
Medical Interview Form

Medical Interview Form

Date:

Patient's Name:

Please note:

- Use black ball-point pen. Do not use water-based ball-point pen.
- If you made a mistake, draw a line across the incorrect data. Do not use correction fluid or any other method of erasure.

Select only one answer from I to IV to each question given below, considering your overall health conditions within the latest seven days, and tick off with a circle between the parentheses:

1. Have you had a burning feeling, rising from the stomach or lower part of the chest towards the neck?

( ) I: I had no symptom.

( ) II: I had symptom but I tolerated it easily.

( ) III: I had symptom with discomfort sufficient to cause interference with normal activities (eating, working, sleeping, etc.).

( ) IV: I was not able to perform normal activities (eating, working, sleeping, etc.).

2. Have you had flow of sour or bitter fluid into mouth?

( ) I: I had no symptom.

( ) II: I had symptom but I tolerated it easily.

( ) III: I had symptom with discomfort sufficient to cause interference with normal activities (eating, working, sleeping, etc.).

( ) IV: I was not able to perform normal activities (eating, working, sleeping, etc.).

3. Have you had central upper abdominal pain?

( ) I: I had no symptom.

( ) II: I had symptom but I tolerated it easily.

( ) III: I had symptom with discomfort sufficient to cause interference with normal activities (eating, working, sleeping, etc.).

( ) IV: I was not able to perform normal activities (eating, working, sleeping, etc.).

4. Have you had difficulties in swallowing?

( ) I: I had no symptom.

( ) II: I had symptom but I tolerated it easily.

( ) III: I had symptom with discomfort sufficient to cause interference with normal activities (eating, working, sleeping, etc.).

( ) IV: I was not able to perform normal activities (eating, working, sleeping, etc.).

Clinical Study Protocol: Supplement A

Drug Substance	D961H
Study Code	D961HC00006
Supplement Edition Number	1
Supplement Date	

Supplement A
Investigators and Study Administrative Structure